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The final menstrual period defines menopause and signifies depletion of ovarian follicular 
reserve and endogenous estradiol. Diminished estradiol underscores postmenopausal increases 
in chronic health conditions of non-reproductive tissues namely the vascular, skeletal, and 
central nervous systems. Polycystic ovary syndrome (PCOS) is a prevalent disorder associated 
with an increased risk for type 2 diabetes and an adverse cardiovascular disease (CVD) risk 
profile evident at younger ages. It is well established that the risk of CVD increases among 
women following menopause. However, no definitive studies exist demonstrating increased 
cardiovascular morbidity or mortality among older women with a history of PCOS. Further, the 
association between menopause and CVD risk factors has not been fully explored in women with 
a history of PCOS. Women with PCOS report less menstrual cycle irregularity across time that 
may reflect varying degrees of ovarian function that in turn may augment CVD risk factors. We 
evaluated the hypotheses that menopause and lifetime menstrual cycle irregularity would have a 
modifying effect on CVD risk factors and markers of subclinical atherosclerosis in 152 women 
with PCOS and 169 normal reproductive controls ages 35 to 67 years. We found that the typical 
reproductive presentation and the adverse lipid profile observed in younger PCOS women was 
not as apparent in older PCOS cases compared to controls. Twenty-five percent of menopausal 
cases, however had type 2 diabetes. Coronary artery calcification (CAC) was greater in cases 
compared to controls and increased with age. PCOS cases reporting the greatest menstrual 
irregularity across time had higher total and free testosterone levels and greater CAC compared 
to cases with more frequent cycles. Our studies support the importance of diabetes prevention in 
aging women with a history of PCOS to reduce risk for early cardiovascular disease. Further, 
women with PCOS who present with the greater cycle irregularity may be more likely to have 
cardiovascular consequences. Relevance to Public Health: Because preventing PCOS is 
unlikely, interventions focused on promoting healthy aging among women with a history of the 
condition represents an important undertaking that will temper long-term health burden and 
improve quality of life.  
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PREFACE 
 
 
Reflecting on my professional experiences and the bumps and stalls that occurred on the 
protracted course of my graduate studies, I have come to appreciate the lessons of each and 
realize those obstacles served to preserve my career pathway in women’s health research; an 
area that has been personally rewarding, intellectually stimulating, and appreciably worthwhile.  
Many individuals influenced and encouraged me during my doctoral training and merit 
recognition and my gratitude. First and foremost they are:  my children, Lindsey and Zachery 
Daniels, sources of inspiration and reminders of the truly important things in life; Scott 
Thomaston, infallible in his encouragement and understanding; my parents for modeling a 
strong work ethic and sense of responsibility and encouraging my independence; Lyn Cost 
whose hospitality and friendship I hold dear; Elizabeth Shire for imparting her passion for 
scientific inquiry and lifelong learning; friends, colleagues, and mentors in the Department of 
Gynecology and Obstetrics at Emory and especially, Ira Horowitz, Georgia Brogdon, Lisa 
Haddad, and Melissa Kottke for the sponsorship, coaching, opportunity, and goodwill they 
expressly contributed; Sarah Berga who introduced me to clinical investigation and stipulated 
an environment that allowed me to develop beyond my job title and position; the members of 
my committee for providing thoughtful mentorship,  direction, and support in the execution of 
this dissertation; and lastly, Evelyn Talbott for suggesting during a CHARM I working group 
that I sign up for an Epidemiology class. She acquainted me with an alternate pathway, and I am 
indebted to her for encouraging me to consider the field of Public Health. I look forward to 
applying the knowledge and expertise gained in graduate preparation as I continue to develop as 
a researcher and advocate for women’s reproductive health.  
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1.0     INTRODUCTION 
 
Polycystic ovary syndrome (PCOS) manifests as anovulatory infertility with androgen 
excess and predisposes metabolic syndrome. These features coexist to varying degrees resulting 
in a spectrum of reproductive, endocrine, and metabolic presentations that affect a significant 
proportion of women. PCOS increases the risk for type 2 diabetes and is associated with adverse 
cardiovascular disease (CVD) risk profiles as well as evidence of subclinical atherosclerosis at 
earlier ages(1, 2). The etiology of PCOS remains undefined despite considerable research. 
Variants in genes regulating steroid biosynthesis, insulin receptor, and follistatin have been 
associated with PCOS in some studies however it is generally agreed that complex gene-
environment interactions likely influence the spectrum of clinical presentation(3, 4). Treatments 
focus on the improvement of the patient’s presenting symptom(s) and may include oral 
contraceptives to regulate menstrual cycles, ovulation induction when pregnancy is desired, and 
behavioral, pharmacological and/or medical interventions to address metabolic symptoms(5).   
In spite of the strong association between PCOS and metabolic syndrome, definitive 
evidence of an increased rate of morbidity or mortality due to cardiovascular events does not 
exist. Advancing chronologic age has been associated with an increase in menstrual cycle 
frequency (6) accompanied by a decrease in androgen levels (7) among women with PCOS. 
Compared to women with normal reproductive histories, those with PCOS possess greater 
numbers of primary ovarian follicles (8) that remain viable and responsive to stimulation with 
advancing age (9). Together these observations suggest a normalization of reproductive function 
with age in PCOS. This notion is intriguing in the context of long-term health risks; for it is 
known that women who experience premature or early menopause are observed to be at 
increased risk of early cardiovascular, skeletal, psychological, and neurological morbidity and 
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mortality (10). Moreover, women who experience rapid transition to menopause demonstrate 
accelerated progression of preclinical CVD indicators compared to women with a slower 
menopause transition (11). There is however a paucity of information about the menopause 
transition in women with PCOS and how menopause effects CVD risk in this population. 
Reasons for this gap include the relatively recent availability of diagnostic and research tools 
necessary to evaluate endocrine and reproductive function, inconsistency with regard to the 
definition of PCOS and menopause, and the limited number of longitudinal studies following 
women with a history of PCOS through middle and older age.  
The significance of this knowledge gap was recognized by the European Society for 
Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive 
Medicine (ASRM) during the 2010 Amsterdam PCOS consensus meeting. Published in 2012, the 
consensus report identified several areas for future inquiry related to PCOS and menopause 
including, the evaluation of the age of menopause, characterization of the PCOS menopause 
phenotype, and the initiation of multi-center, longitudinal cohort studies to assess the 
menopause phenotype as well as long-term risk of morbidity and mortality among women with 
a history of PCOS (12). The Cardiovascular Health and Risk Measurement (CHARM) study 
directed by Dr. Evelyn Talbott began as a matched case-control study aimed at evaluating CVD 
risk factors in women with documented PCOS and their normal reproductive control 
counterparts during the middle to late reproductive years. A significant proportion of the 
participants were re-evaluated after 10 years during CHARM phase III. Our study examines the 
association between PCOS and menopause on CVD risk factors and subclinical atherosclerosis 
in PCOS cases and controls evaluated in their late reproductive to early menopausal years 
during CHARM-III. 
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1.1 Hypothesis and Specific Aims 
 
Young women with PCOS have increased CVD risk factors and subclinical 
atherosclerosis and it is well known that the risk of CVD increases among all women following 
menopause. The association between menopause and cardiovascular disease risk factors has not 
been fully explored in older women with a history of PCOS. Further, women with PCOS report 
varying degrees of menstrual cycle irregularity that may reflect varying degrees of ovarian 
function, (estrogen exposure) that in turn may augment cardiovascular risk factors. Recently it 
was shown that the decrease in estradiol and stable androgen levels associated with the 
menopausal transition in women with normal reproductive history led to a state of relative 
androgen excess that resulted in an increase risk for metabolic syndrome (13). Conversely, 
among women with PCOS there is evidence indicating that androgen levels decline and 
menstrual cycles become more frequent with age. Women with PCOS also display elevated 
ovarian anti-müllerian hormone (AMH) levels compared to normal reproductive women. Both 
AMH and estradiol are produced by granulosa cells of the ovarian follicle. To date the 
relationship between AMH level and androgen to estradiol ratio in an older reproductive age 
group of women with a history of PCOS has not been documented. This investigation will 
examine the associations between PCOS, menopause, menstrual irregularity, and CVD risk 
factors and subclinical atherosclerosis in a cohort of middle adult women who participated in 
the Cardiovascular Health and Risk Measurement III (CHARM-III) study. 
 
Specific Aim 1: examine the association between menopause and CVD risk factors and 
subclinical atherosclerosis (SCA) as determined by coronary artery calcification (CAC) in 
middle-aged women with a history of PCOS and controls adjusting for age, body mass index, as 
well as other known predictors of CVD risk factors. 
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Hypothesis 1: menopause will further exacerbate risk factors for CVD and subclinical SCA in 
older women with a history of PCOS compared to controls. 
  
Specific Aim 2: examine the association between degree of menstrual irregularity, determined 
by number of cycles reported across earlier reproductive years, and CVD risk factors and CAC 
among women with PCOS who were evaluated during later reproductive to menopausal years. 
Hypothesis 2: greater menstrual irregularity across time will be associated with a more 
adverse CVD risk profile and SCA documented by CAC in women with a history of PCOS. 
 
Specific Aim 3: examine the relationship between ovarian reserve, documented by anti-
müllerian hormone (AMH) level and relative testosterone to estradiol ratio, documented by the 
ratio of free androgen index to free estradiol index (FAI/FEI) in late reproductive age women 
with PCOS compared to controls. 
Hypothesis 3: decreases in AMH level will be associated with an increased FAI/FEI ratio in 
both PCOS and controls. PCOS will have a smaller change in FAI/FEI that correlates with a 
higher AMH level. 
 
To summarize, PCOS is associated with an increased the risk for chronic health 
conditions that extend well beyond the reproductive portion of a woman’s life. Limited data is 
available on the relationship between PCOS, menopause, and risk factors for cardiovascular 
disease. Preventing PCOS is unlikely, thus, developing strategies to facilitate healthy aging 
among women with the condition represents an important undertaking that will contribute to a 
reduction of long-term health burden. The information garnered from this investigation may 
result in better strategies for management of PCOS through the menopause transition and 
ultimately improve health and quality of life for those with the disorder. 
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2.0 BACKGROUND AND RATIONALE 
 
This section provides a: 1) general overview of the history, definitions, and prevalence 
of PCOS; 2) description of the reproductive and metabolic attributes of PCOS; 3) review of the 
physiological processes that define normal reproductive function and the menopause 
transition; 4) summary of our current understanding of aging in women with PCOS; and 5) 
framework for the proposed studies to evaluate the association between menopause, lifetime 
cycle irregularity and risk factors for cardiovascular disease and subclinical atherosclerosis in 
women with a history of PCOS.   
 
2.1 Polycystic Ovary Syndrome: History, Definition, and Prevalence 
 
 
In 1935, surgeons Stein and Leventhal published a case series describing the appearance 
of enlarged ovaries containing multiple small cysts in a group of amenorrheic, hirsute, women 
undergoing wedge resection (removal of a section of ovary). They observed that wedge resection 
was followed by restoration of menstrual cyclicity in these patients (14). Advances in laboratory 
medicine and medical imaging have since enabled physicians and scientists to further 
characterize the endocrine, metabolic, genetic, and morphologic features of this presentation; a 
condition now referred to as polycystic ovary syndrome (PCOS). PCOS is characterized by a 
range of clinical and endocrine features including, intermittent ovulation and menses, excess 
body hair, acne, central obesity, elevated serum levels of ovarian androgens and pituitary 
luteinizing hormone (LH), insulin resistance, and ultrasonographic appearance of polycystic 
ovaries. Heterogeneity in clinical presentation contributed to inconsistencies in the diagnosis 
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and definition of PCOS that hampered evaluation and comparison of studies published in the 
early literature. 
Demands from the scientific and medical communities for uniformity in the definition of 
PCOS led to a 1990 National Institutes of Health (NIH) conference to develop criteria for the 
classification of PCOS. Although a consensus was not reached, it was generally agreed that PCOS 
would be defined as chronic oligo- or anovulation accompanied by clinical and/or biochemical 
evidence of ovarian hyperandrogenism that was exclusive of other causes such as congenital 
adrenal hyperplasia or androgen secreting tumors (15). Attendees were divided on ovarian 
ultrasonographic findings. Because polycystic ovaries had been observed in some women with 
normal reproductive function (16) and had not been observed in all women with PCOS (17) the 
appearance of polycystic ovaries on ultrasound was not deemed necessary for the diagnosis of 
PCOS.   
In 2003 ESHRE/ASRM held a conference in Rotterdam and ratified an expanded 
definition of PCOS to include ovulatory and anovulatory women with polycystic appearing 
ovaries and normal androgen levels (18). Women with these presentations would not have met 
criteria for PCOS using the classic NIH definition. Many experts viewed the new definition 
premature voicing concerns about the integrity of future research, clinical management, and 
patient insurability (19) if women with polycystic ovaries who did not also display androgen 
excess or ovulatory dysfunction were now considered to have PCOS. Evidence in support of both 
the exclusion and inclusion of these presentations can be found in the literature. Johnstone et al 
studied 262 ovulatory women and found that 32% of the subjects had evidence of polycystic 
ovaries on ultrasound but there was no association with metabolic perturbations typically 
observed in women with PCOS (20). Conversely, the fertile sisters of infertile women with PCOS 
often have some but not all of the features associated with classic PCOS and may be considered a 
reflection of the full spectrum of PCOS presentations (21). The Androgen Excess and PCOS (AE-
PCOS) Society organized a taskforce to reconcile the NIH and Rotterdam definitions and 
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published a blended definition in 2009. The AE-PCOS defined PCOS as hyperandrogenemia 
(clinical and/or biochemical) and ovarian dysfunction (oligo-anovulation and/or polycystic 
ovaries) with other causes of androgen excess excluded (22) (23). Table 1, contrasts the NIH, 
Rotterdam, and AE-PCOS definitions for ten possible combinations of PCOS features.  
Using the classic NIH definition, PCOS affects between 4% and 11% of all women (24). 
The prevalence increases 1.5 fold when the Rotterdam criteria are applied (25). PCOS is the 
underlying cause of infertility in 30% of women seeking evaluation for anovulation (26) and is 
present in 82% of women seeking evaluation for androgen excess (27). Carmina et al, evaluated 
950 women with androgen excess using the Rotterdam criteria and found classic anovulatory 
PCOS in 60% and ovulatory PCOS in 15% of participants (28). Several teams have examined the 
degree of metabolic derangement across PCOS phenotypes and there is agreement that classic 
PCOS (hyperandrogenism combined with anovulation) is associated with more adverse 
metabolic and cardiovascular risk profiles compared to more subtle PCOS types (29-31).  The 
overwhelming majority of women with PCOS (75%) meet the classic NIH definition (2). 
Although PCOS is not isolated to any one particular race or ethnicity, evidence supports 
variability in the clinical phenotypic presentation between racial and ethnic groups. Lo et al, 
evaluated the cardiovascular risk profiles in 11,000 women diagnosed with PCOS in the Kaiser 
Permanente of Northern California health system. She found that women with PCOS of Asian 
descent were less likely and PCOS women of African or Hispanic origin were more likely to be 
obese compared to Caucasian women with PCOS. In addition, Asian and Hispanic women with 
PCOS were more likely to have diabetes (OR 2.16, 95% CI 1.63-2.85 and OR 1.33, 95% CI 1.03-
1.71) compared to Caucasian women with PCOS. African American participants with PCOS were 
more likely to have hypertension  (OR 1.32, 95% CI, 1.19-1.48) compared to PCOS cases of other 
races and ethnic groups (32). Using the NIH criteria, Welt et al studied 105 women with PCOS 
from Iceland and 262 women with PCOS from Boston and found that hormone levels 
(androgens and gonadotropins) and Ferriman and Galway scores (measure of hirsutism) varied 
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between ethnic groups but glucose and insulin levels were conserved across groups when 
adjusted for BMI (33). Together, these studies reinforce the concept that PCOS is a common, 
multifaceted, chronic condition that affects women across all races and ethnicities with 
implications for negative health consequences that surpass the reproductive portion of a 
woman’s lifespan.  
 
2.2 Reproductive Attributes of PCOS 
 
Normal ovarian function results when neurons of the hypothalamus operate in 
synchrony releasing pulsatile bursts of gonadotropin releasing hormone (GnRH) that stimulate 
the anterior pituitary to secrete luteinizing hormone (LH) and follicle stimulating hormone 
(FSH). During the early follicular phase, FSH exceeds LH causing primary ovarian follicles to 
mature. Later, LH secretion surpasses FSH and a dominant follicle emerges. As the follicle 
matures it produces increasing amounts of estradiol (E2). Roughly 14 days from the onset of the 
last menstrual period, LH and E2 surge and a mature oocyte is released from the dominant 
follicle. Pulsatile release of LH and FSH slows and levels fall as residual follicular cells (corpus 
luteum) secrete progesterone and a second wave of E2 preparing the uterus to receive a 
fertilized egg. In the absence of conception, progesterone peaks around day 21 and falls rapidly 
resulting in endometrial shedding (menses) and the beginning of the next cycle (34, 35).    
The first menstrual period defines menarche and denotes the pubertal transition. The 
median age of menarche has held relatively constant in recent history at 12.43 years. Females of 
African and Hispanic decent experience the first menstrual period at slightly earlier ages, 12.06 
and 12.25 years respectively and girls with higher BMI also tend to experience earlier pubertal 
development (36). Menstrual onset does not however equate reproductive competence; rather a 
number of years may pass before the reproductive axis fully matures to support cyclic ovulation 
(36, 37). For this reason the diagnosis of irregular menses in the adolescent population is 
challenging. 
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Irregular menstrual cycles with intermittent ovulation is a cardinal feature 
of PCOS. Women with PCOS display increased pulsatile secretion of luteinizing hormone (LH) 
(38) that is resistant to feedback suppression by sex steroids (39). LH levels consistently exceed 
(FSH) levels as evidenced by a LH:FSH ratio greater than 1. Limited FSH stimulation is 
associated with the development of multiple small follicles rather than a dominant follicle, 
leading to the pattern of chronic anovulation and oligomenorrhea characteristic of PCOS. PCOS 
is often is detected in adolescence and patients with an early presentation are often at highest 
risk for metabolic complications (40). 
Women with PCOS display evidence of increased ovarian androgen 
secretion. Normally, LH stimulates the cells of the follicle’s outer theca layer to produce 
androstenedione, which is converted to testosterone and ultimately aromatized to estradiol by 
granulosa cells of the follicle’s interior. Several potential explanations exist for ovarian androgen 
excess in PCOS including, 1) increased sensitivity of the theca to LH and insulin stimulation; 2) 
a decreased rate of conversion to E2 via aromatase activity in the granulosa cells; and 3) 
increased number of follicles contributing to the pool that is able to secrete androgens (41). 
Clinically androgen excess in PCOS is associated with acne, alopecia, and hirsutism. 
Testosterone levels in women with PCOS are typically elevated but lower than that observed in 
men, thus, significant virilization in the female patient is an indicator of a non-ovarian androgen 
source and warrants further evaluation (15, 18, 22).   
Androgens produced by follicles of the PCOS ovary are converted to estradiol. Because 
ovulation does not regularly occur there is no luteal phase surge in progesterone to oppose this 
tonic level of estrogen. Untreated, unopposed estrogen exposure in women with PCOS 
contributes to the increased risk of endometrial carcinoma (42). Ovulation occurs spontaneously 
in PCOS and can also be achieved with correction of gonadotropin aberrations (43, 44). Other 
reproductive consequences of PCOS include ovarian hyperstimulation syndrome with ovulation 
induction, miscarriage, gestational diabetes, preeclampsia, and preterm birth with pregnancy.  
 
 
10 
Ovarian enlargement coupled with the appearance of multiple small follicles 
on ultrasound evaluation is a common feature of PCOS. During fetal development 
ovarian germ cells undergo mitotic replication; increasing in number until just prior to birth 
they enter meiosis forming primordial follicles, the basic functional units of the ovary. When 
mitotic replication ceases the ovary becomes endowed with a complete complement of follicles 
for life. Around the time of birth a significant proportion of this cohort is lost through atresia 
and growth of remaining follicles is arrested until puberty. Then with puberty follicles from the 
primordial pool enter the growing pool. A small number (roughly 500) of the estimated 2 
million follicles endowed at birth, are destined for ovulation. Unselected follicles in the growing 
pool are eventually lost to atresia. Menopause ensues with depletion of the growing follicle pool. 
The polycystic appearing ovary (PAO) is characterized by a thickened stromal core and 
increased number of small pre-ovulatory follicles (8). LH and insulin stimulation of the theca 
cells contribute to this observed thickening of the ovarian stroma and to the increase number of 
ovarian follicles with an increase in ovarian volume characteristic of the polycystic ovary (41). 
Possible explanations for the increased number of follicles in the ovaries of women with PCOS 
include a greater number of primordial follicles, increased entry of primordial follicles into the 
growing pool, and/or decreased clearance through atresia (45).   
The evidence for increased numbers primordial in PCOS is inconsistent (8, 46, 47). 
However, there is agreement that the number primary growing follicles is greater in women with 
PCOS compared to those with normal reproductive history (46, 47). However, the explanation 
for this observation is less clear and may be due to an increased recruitment from the resting to 
the growing pool and/or a delay in clearance from the growing pool via apoptosis (atresia) (46, 
48). Nevertheless, in vitro and in vivo studies demonstrate small arrested follicles of the PCOS 
ovary are responsive to appropriate hormonal stimulation (49) (50).    
Biochemical evidence supports an increased follicle cohort in PCOS. Anti-
müllerian hormone (AMH) belongs to the transforming growth factor beta (TGFβ) family of 
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cytokines, is produced by the granulosa cells of the developing follicle, and is believed to play a 
role in follicle selection (51). With increasing age, AMH decreases in direct correlation with 
declining follicle count and because levels are consistent across the menstrual interval it is 
preferred to inhibin B and FSH as a biochemical marker of ovarian reserve (51, 52). Elevated 
AMH levels are evident in women with PCOS from adolescence through the later reproductive 
years (53-55). Interestingly, in vitro studies have shown that this increase is not entirely due to 
an increase in follicle number rather granulose cells of the PCOS have higher rates of AMH 
production compared to cells from the ovaries of women with normal reproductive history (56). 
 
2.3 Metabolic Attributes of PCOS 
 
The coexistence of metabolic symptoms, hyperandrogenemia, and reproductive 
compromise was documented by Stein and Leventhal in their 1935 case series (14). In the years 
since that initial report, the metabolic sequelae associated with PCOS have been further 
characterized. Affected women frequently display increased central adiposity, obesity, 
hyperinsulinemia, type 2 diabetes, hypertension, an atherogenic lipid profile, an increase in 
inflammatory markers, and evidence of early subclinical atherosclerosis(57). The strong 
association with insulin resistance led to the inclusion of PCOS diagnosis as a major risk factor 
for the development of type 2 diabetes (1). Moreover, in 2010 the Endocrine Society in 
conjunction with the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society 
commissioned an evidence-based review and evaluation of existing literature and development 
of guidelines for the prevention of cardiovascular disease specific to women with the condition 
(2).  
Women with PCOS are at increased risk for developing type 2 diabetes. 
Insulin resistance independent of obesity is a cardinal feature of PCOS (58). Two independent 
investigations estimate the prevalence of insulin resistance to be between 60% and 80%, and 
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nearly all obese women with PCOS are also insulin resistant (59, 60). Impaired glucose 
tolerance affects between 30-35% of women with PCOS and approximately 10% will also have 
type 2 diabetes (61, 62). Recent studies suggest that 40% of women with PCOS will go on to 
develop pre- or frank diabetes by age 50 (63, 64). Obesity is a contributing factor, however even 
non-obese women with PCOS have abnormal glucose metabolism (58).   
Women with PCOS have an adverse risk profile for cardiovascular disease. A 
number of reports documenting increased levels of CVD risk factors in women with PCOS 
compared to women with normal reproductive function have been published. Dahlgren et al, 
evaluated 33 women who underwent wedge resection two to three decades prior to evaluation 
and found an increased prevalence of diabetes and hypertension (65) and on further analysis 
calculated a 7 times greater risk for myocardial infarction in the PCOS cases compared to a 
group of 132 age matched controls (66). In another study of 102 women with PCOS and 19 lean 
normal reproductive controls, hypertension was observed in 6% of lean and 17% of obese PCOS 
subjects. This effect was only partially explained by insulin levels. Fasting glucose and 
androstenedione levels also contributed to the effect on blood pressure (67).   
The Cardiovascular Health and Risk Measurement (CHARM) study, led by Dr. Talbott at 
the University of Pittsburgh represents one of the largest and well characterized prospective 
assessments of CVD risk among women with PCOS, Table 2, NIH R01HL4664-01. This 
investigation included 244 PCOS cases defined by the 1990 NIH criteria and 244 community, 
age, and race matched normal reproductive controls. The average age of women in CHARM I 
was 35 years and the cohort was predominantly white (92.4%). PCOS cases exhibited a more 
atherogenic risk profile that was evident in the premenopausal period (68) and independent of 
ultrasound ovarian appearance (69). PCOS predicted a more adverse lipid profile at younger 
ages when compared to control women (70). Middle-aged women with PCOS may be at risk for 
premature carotid atherosclerosis (71, 72), an observation that could not be fully explained by 
adjustment for body mass index (BMI). More recently, Talbott et al have shown that PCOS is 
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associated with increased calcification in the aorta and coronary arteries but the effect of PCOS 
is largely mitigated by the severity of indicators of the metabolic syndrome (73, 74).  
Polycystic appearing ovaries are observed more often in women undergoing coronary 
angiography (75). However when Pierpoint et al, evaluated a group of 786 women with 
histologic evidence of PCOS in their late 20s there was no observed increase in CVD mortality at 
follow-up some 30 years later (76). The Dahlgren cohort was again evaluated at age 70 years. Of 
the 25 PCOS subjects evaluated and 68 controls there was evidence of elevated triglycerides and 
more hypertension in the cases but morbidity and mortality was the same across groups (33 
cases and 95 controls) after controlling for BMI (77). FSH levels remained lower and free 
androgen index higher between cases and controls after menopause. The difference in waist hip 
ratio between cases and controls observed at younger ages were no longer evident in the older 
cohort and was likely due to weight gain among the controls. The authors also found a higher 
prevalence of hypothyroidism in controls (34%) compared to PCOS cases (8%) (78). The 
patients of the Pierpoint study were relatively young to be assessed for CVD morbidity and 
mortality and the Dalgren group small.  These studies also evaluated events, we will evaluate 
women around the time of the menopause transition and examine the relationship between 
PCOS and menopause on CVD risk factors and SCA. 
In 2008, Talbott et al evaluated the effect of menopause on coronary artery calcification 
in 128 cases and 166 controls participating in the third CHARM follow-up. PCOS continued to 
be associated with increased coronary calcification, however among PCOS women who reported 
surgical menopause their coronary artery calcification scores were significantly greater than 
controls undergoing surgical or natural menopause (79). Similar findings with regard to risk for 
progression of preclinical CVD as documented by intima media thickness (IMT) in women who 
experienced a more rapid menopause transition were published by Johnson et al in 2010. In 
their sample of 203 women with no prior diagnosis of CVD, those women who transitioned from 
a pre- to a post-menopausal state within the 3 year observation period exhibited an increased 
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rate of disease progression compared to those who were continuing to transition (11). Further, 
women undergoing bilateral oophorectomy before age 45 had a 1.44 times greater risk of dying 
from CVD compared to control population (80).  
 
2.4 Aging and PCOS 
 
There is a paucity of information on the menopause/perimenopause transition in PCOS. 
The knowledge gap related to reproductive aging in PCOS was recently identified as a priority 
research area by the ESHRE/ASRM (12). The final menstrual period (FMP) retrospectively 
defines menopause. Analogous to the interval immediately following menarche, the interval 
preceding the final menstrual period is associated with fluctuating hormone levels, changes in 
menstrual cycle number and duration, and intermittent ovulation. The effects as well as the 
other symptoms of menopause (hot flashes, sleep disturbances, change in mood) are related to 
ovarian aging and follicle demise as well as changes in the sensitivity of the hypothalamic-
pituitary axis to sex steroid feedback (81). Just as the definition and diagnosis of PCOS was 
inconsistent, so too was the diagnosis of menopause. In 2001, the major professional societies 
for reproductive medicine, menopause, and NIH co-sponsored the Stages of Reproductive Aging 
Workshop (STRAW) to develop uniform criteria and nomenclature for staging reproductive 
aging in women. The STRAW menopause staging system is based largely on a woman’s self-
reported changes in menstrual interval and therefore not generalizable to those who have a 
history of irregular cycles, are extremely under or overweight, or smoke (82).  By definition 
PCOS is associated with cycle irregularity and therefore the STRAW criteria would not be 
suitable for determining  menopause transition in women with a history of the condition. 
The timing of menopause is influenced by a number of modifiable and non-modifiable 
factors that include ethnicity and socieconomic status, weight, exercise, and smoking.  Typically  
evidence of the perimenopause (i.e., menstrual irregularity) can be detected  around age 45 with 
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menopause occurring about 6 years thereafter [For review see Gold E.  2011 Obstet Gynecol Clin 
North Am 38:425-440](83). The age and timing of the menopause transition is important 
because of the increase in long-term health risks to non-reproductive systems that are 
associated with early and rapid loss of estrogen (10, 11, 83). 
Aging has been associated with normalization of menstrual cycle 
irregularities and androgen excess associated with PCOS. Elting and her colleagues 
published a retrospective study evaluating cycle patterns in 205 women previously diagnosed 
with PCOS (6). The average follow-up interval was approximately 12 years and participants were 
between 30 and 56 years of age. Sixty percent of the women participating reported a cycle 
interval of <6 weeks and this was inversely correlated with age (p<0.001). Logistic regression 
analyses accounting for BMI, weight loss, smoking, ethnicity, prior hormonal treatments, and 
prior pregnancy had no impact on the effect of aging on menstrual cycle frequency in PCOS. The 
team then prospectively evaluated 27 women with a prior diagnosis of PCOS who were between 
the ages of 36 and 50. Each underwent an FSH stimulation test to measure of ovarian reserve 
and received a transvaginal ultrasound scan to determine follicle number. Twenty women 
reported menstrual intervals of less than 6 weeks and seven women reported intervals greater 
than 6 weeks. Women with regular cycles were older (median age 40.9 yrs) and leaner (median 
BMI 24.3 kg/m2) compared to women with irregular cycles (median age 38.8 years, p<0.04; 
median BMI 29.1 kg.m2, p<0.07). Women with PCOS who reported regular cycles had 
significantly lower testosterone and androstenedione levels and higher FSH levels compared to 
those with irregular cycles. These women also had approximately half the number of ovarian 
follicles (median follicle number 8.5) compared to women with irregular cycles (median follicle 
number 18.0, p<0.01)(84). Another study of 472 women with a diagnosis of PCOS showed a 
statistically significant correlation between increasing age and decreasing cycle interval. 
Significant reductions in testosterone, androstenedione, LH, and follicle number in older (ages 
30-42) compared to younger (ages 17-29) were also noted (85).   
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The effect of age on testosterone was previously evaluated in a subset of women 
participating in CHARM I. Winters et al documented a 50% reduction in total and free 
testosterone levels in PCOS cases 42-47 years of age compared to PCOS cases between 20 and 
42 years of age (7). When they compared androgen levels between PCOS cases and normal 
reproductive controls by age quartile, statistically significant differences between groups at the 
youngest and oldest strata were observed but testosterone levels were comparable between cases 
and controls in the 42-47 year age quartile (7). The overall trend among PCOS cases was toward 
a reduction in androgen levels with increasing age however, testosterone levels remained higher 
in older PCOS cases compared to older controls suggesting continued ovarian responsiveness to 
LH or insulin stimulation.  
Recently, two separate groups reported that both the adrenal gland (86) and the ovary 
(86, 87) contribute to postmenopausal hyperandrogenism in women with a prior PCOS 
diagnosis. Markopoulos et al evaluated 20 postmenopausal women with a past diagnosis of 
PCOS and 20 postmenopausal controls of similar age, years since menopause, BMI, and percent 
body fat. PCOS women registered greater waist circumference and waist to hip ratio as well as 
baseline elevations in androgen levels and free androgen index (FAI) and decreased sex 
hormone binding globulin (SHBG) levels compared to controls (86). When stimulated with 
adrenal corticotrophin releasing hormone (ACTH) postmenopausal PCOS and controls 
exhibited similar androgen responses. A 3-day dexamethasone suppression treatment yielded 
reductions in adrenal and ovarian hormones in both groups but PCOS exhibited less 
suppression of androstenedione, 17-OHP, and FAI compared to controls (86). Puurunen and 
colleagues evaluated 50 women in four groups; PCOS (n=11), controls (n=10), postmenopausal 
PCOS (n=18) and postmenopausal controls (n=11) before and after oral glucose tolerance testing 
and stimulation with human chorionic gonadotropin (hCG). They found persistent insulin 
resistance and high C-reactive protein in pre- and post-menopausal PCOS groups compared to 
pre- and post-menopausal controls. In addition, the postmenopausal PCOS group had 
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androstenedione responses to hCG stimulation that were nearly two fold greater than 
postmenopausal controls (1,000 ± 313.8 vs. 531.3 ± 40.3, p=0.035). The androstenedione 
response among postmenopausal PCOS and premenopausal controls was similar (87). 
One longitudinal study exists demonstrating a change over time in reproductive indices 
and androgen levels among women with PCOS (88). A group of 254 women with PCOS defined 
by the Rotterdam criteria were evaluated at baseline and again approximately 2.6 (n=172) or 5.5 
(n=84) years later. A reduction in serum testosterone levels was observed and a small 
proportion of women in the PCOS group (4.4% to 4.6%) reporting regular menses between the 
first and second visits (88). This investigation provided limited information on the menopause 
transition due to the young ages at baseline (24.9 to 30.9 years) and follow-up (35.5 years) (88).   
Do older women with PCOS have more fertility? A large study from Norway 
evaluated birth rates in 500 women with PCOS and 500 control women who underwent IVF. 
These investigators found that older age was associated with a reduced number of oocytes 
retrieved and reduced live birth rates in control but not PCOS subjects (9) which suggests a 
longer window of fertility in women with PCOS.  
Collectively, these data support the notion that women with PCOS have sustained 
ovarian function and conceivably have a different progression toward ovarian senescence 
compared to women with normal reproductive histories. Sustained ovarian activity may 
translate to longer duration of estradiol exposure and thus modify CVD risk factor progression 
among PCOS. Further, individual variability in ovarian activity across the reproductive window 
as evidenced by degree of cycle irregularity or degree of cycle control through use of oral 
contraceptives may influence CVD risk factors in this population. To the best of our knowledge 
this has not been examined in a large well characterized group of women with a history of PCOS. 
Ultimately, longitudinal studies are needed fully characterize reproductive aging and the 
menopause transition in PCOS and to explicate the relationship between menopause and 
chronic disease risk in this population.    
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2.5 Summary 
 
PCOS affects a significant proportion of women, has a recognized metabolic component, 
and contributes to increased long-term health burden for the individual and society. Young 
women with PCOS present with increased CVD risk factors. Menopause furthers the risk for 
CVD among women. Limited data is available on the relationship between PCOS, menopause, 
and risk factors for cardiovascular disease. Our approach to address this knowledge gap 
evaluated data collected as part of the CHARM III study. This study included a group of well-
characterized cases with a history of PCOS and a group of normal reproductive controls whose 
average age was between 47-49 years who submitted to a detailed reproductive history with 
hormonal assessments and evaluation of CVD risk factors and subclinical atherosclerosis. 
Understanding the relationship between menopause and CVD risk factors in women with PCOS 
is warranted so that appropriate management strategies can be developed and applied to 
facilitate healthy aging. The information garnered from this investigation may result in better 
strategies for management of PCOS through the menopause transition and ultimately improve 
health and quality of life for those with this disorder.  
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2.6 Tables Section 2.0 
Table 1. Comparison of the National Institutes of Health (NIH), Androgen Excess PCOS society (AE-PCOS), and 
Rotterdam PCOS definitions for ten different phenotypic presentations 
Feature 
Phenotypic 
Presentation 1 2 3 4 5 6 7 8 9 10 
Hyperandrogenism           
Hirsutism           
Oligo/anovulation           
Polycystic Ovaries           
Definition 
NIH (1990) + + + + + +     
AE-PCOS (2006) + + + + + + + + +  
Rotterdam (2003) + + + + + + + + + + 
 
= feature present; + = meets definition; Adapted with permission (19) 
 
 
Table 2. Major findings from Cardiovascular Health and Risk Measurement (CHARM) study (66-73,79) 
Study Year Cases (n) Controls (n) 
Age ± SD 
(yrs) Primary Finding (s) 
Talbott, et al 1995 
206 35.9 ± 7.4 • ↑ total cholesterol, LDL, triglycerides, and 
insulin and ↓ HDL in PCOS  
• Differences evident at earlier ages 206 37.2 ± 7.8 
Guzick, et al 1996 16 44.4 ± 3.6 • ↑ IMT in PCOS  vs. controls 16 43.9 ± 5.2 
Talbott, et al 1998 244 35.3 ± 7.4 • PCOS predictive of total cholesterol and LDL at younger rather than older ages 244 36.7 ±7.7 
Loucks, et al 2000 63 35.0 ± 6.3 • Polycystic ovaries did not alter CVD risk 56 38.3 ± 6.7 
Talbott, et al 2000 
125 37.5 ± 6.2 • Older PCOS cases had greater IMT that was 
not explained by age or BMI 142 39.0 ± 6.2 
Talbott, et al 2004a 
61 47.9 ± 5.0 • PCOS predicted CAC; effect mediated by insulin and HDL 
• PCOS 4Xs metabolic syndrome 
• Total testosterone risk factor for aortic 
calcification in PCOS and controls 85 49.2 ± 5.4 
Talbott et al 2004b 
47 49.2 ± 4.0 • No influence of CRP on IMT in PCOS 
• Obesity influenced CRP and IMT in PCOS 
• PCOS may have residual effect on IMT beyond 
insulin and fat mass 59 49.5 ± 3.4 
Talbott et al 2008 
149 47.3 ± 5.6 • Menopause risk factor of CAC 
• Surgical menopause more significant in PCOS 166 49.4 ± 5.8 
LDL-low density lipoprotein; HDL-high density lipoprotein; IMT- intima-media thickness; BMI-body mass 
index; CAC- coronary artery calcification; CRP-C reactive protein 
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3.0 METHODS 
 
3.1 Subjects 
 
The study population included women with PCOS and women with normal reproductive 
history evaluated in their middle to late reproductive years [mean (SD) age of cases 35.3 (7.4) 
and controls 36.7 (7.7) years] for cardiovascular risk factors between 1994 and 1995 (phase I) of 
the CHARM study (70). Participants were re-evaluated in 1997-1999 (CHARM phase II) for 
carotid intima-media thickness (IMT) and in 2000-2006 (CHARM phase III) for cardiovascular 
risk factors and coronary calcification, Table 2.   
CHARM III included three visits that occurred during 2001-2003, 2003-2004, and 
2003-2006. Visits 1 and 3 focused on measurement of coronary calcification and visit 2 focused 
on carotid IMT. The main hypotheses of this dissertation were evaluated from outcomes 
collected during CHARM III visit 1. A total of 152 cases and 169 controls between the ages of 35 
and 67 years participated in CHARM III visit 1. CHARM III visit 3 occurred about 2.8 years later 
and included 121 cases and 154 controls that were evaluated previously at Visit 1, Figure 1. The 
exploratory analysis (Aim 3) included data from visits 1 and 3 in a subset of patients who were 
between the ages of 42-48 years at visit 1. This age range was selected as we were most 
interested in evaluating the outcomes (AMH, estradiol, and androgen levels) during the 
perimenopausal window when ovarian follicular activity wanes. The study was reviewed and 
approved by the Institutional Review Board of the University of Pittsburgh and all subjects 
provided written informed consent prior to the initiation of study procedures.  
A detailed description of the approach to identify cases and controls in phase I has been 
published elsewhere (70). Briefly, PCOS cases were identified through retrospective review of 
medical records of women seen between 1972-1992 for infertility by Drs. David Archer and 
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David Guzick. Medical records resided within reproductive endocrinology and infertility division 
at Magee-Womens Hospital and were reviewed to determine eligibility for inclusion by Dr. 
Evelyn Talbott in 1993-1994. A presumptive diagnosis of PCOS was made based on history of 
chronic anovulation associated with clinical evidence of androgen excess (hirsutism) or if total 
testosterone exceeded 2 nmol/L or the LH/FSH ratio was > 2; criteria consistent with the 1991 
NIH definition of PCOS (15). Neighborhood controls matched for age ± 5 years and race were 
recruited from 1992 voters’ registration tapes for the greater Pittsburgh area and Cole’s Cross 
Reference Directory of households (89). Controls reported regular menses and had no 
complaints of hirsutism or fertility problems. New subjects were added between phases I and III 
in an attempt to increase the heterogeneity of the study population. Newly added cases and 
controls met the same inclusion and exclusion criteria. Loss to follow-up of cases and controls 
made it impractical to maintain the matched design used in CHARM I in the later study phases.  
  
 
3.2 Interventions 
 
CHARM III visits 1 and 3 consisted of a detailed clinical interview that included 
demographic and behavioral information, current and past medical and surgical interventions, 
concurrent and previous medications, and family, reproductive, and menstrual histories. Statin 
use was not a specific question at CHARM III visit 1. To ascertain this information, participants’ 
responses to questions about “other medications” were tabulated to approximate usage. A copy 
of the questionnaire used in the clinic interview appears in the Appendix. Anthropomorphic 
and blood pressure measurements were obtained as well as a fasting blood sample for 
evaluation of reproductive and androgen hormones and metabolic factors. Participants also 
underwent electron beam tomography (EBT) scanning for assessment of coronary artery 
calcification (CAC).  
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Current menstrual history included a description of the number and length of cycles in 
the previous twelve months and date of last menstrual period. If a participant reported no 
menstrual cycles in the previous year, they were asked when their cycle had stopped and the 
reason. Reproductive history included 1) prior reproductive surgery, type, and reason; 2) use of 
fertility medications; and 3) number of pregnancies and births. Participants were queried about 
current and past use of oral contraceptives (OCs), medroxyprogesterone (Provera), and 
hormone replacement therapy (HRT). Past use in months was recorded by decade beginning 
with the teenage years. The average number of menstrual cycles per year and average cycle 
length when not using hormonal contraception or pregnant was also recorded by decade.   
Height (m) and weight (kg) measurements were recorded and utilized to calculate body 
mass index (BMI, kg/m2). Waist to hip ratio (WHR) was determined from the average of two 
measurements taken at the minimum waist circumference and the maximum hip circumference 
(70). Systolic and diastolic blood pressures were determined from the average of two readings 
obtained using a random-zero sphygmomanometer. All participants were told to fast for at least 
twelve hours prior to the office visit. Venipuncture was performed and serum aliquots from 
blood samples were frozen at -80C for later analysis of reproductive hormones, androgens, 
lipids, insulin and glucose.   
 
 
3.3 Laboratory Assessments 
 
Laboratory determinations of insulin, glucose, and lipids were completed for all participants 
seen at visit 1 and visit 3. Luteinizing hormone (LH), follicle stimulating hormone (FSH), 
estradiol (E2), total testosterone (TT), and sex-hormone binding globulin (SHBG) levels were 
analyzed for all visit 1 participants. A subset of participants (38 cases and 40 controls) who 
completed visits 1 and 3 and were between the ages of 42 to 48 years at visit 1 were selected for 
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the exploratory analysis that included determination of anti-müllerian hormone (AMH) levels as 
well as LH, FSH, E2, TT and SHBG in serum collected at both visits 1 and 3. 
 
3.3.1 Biochemical Determinations 
 
Hormone assays were performed at Magee-Women’s Research Institute and Emory 
University, in Atlanta, Georgia in the research laboratory of Dr. Sarah Berga. All analyses were 
run in duplicate and batched to reduce variability. LH and FSH were measured using a 
fluoroimmunometric assay (IFMA) (Delfia hLHSpec and FSH- Perkin Elmer, Fisher Scientific, 
USA).  Interassay and intrassay coefficients of variation (CV) for these methods were less than 
5%. AMH was measured by a highly sensitive enzyme linked immunoassay (ELISA-Beckman 
Coulter). This method has a sensitivity of 0.10 ng/mL and assay variation was between 4 and 
8%.  
Levels of E2 at visit 1 and and TT at visit 1 and visit 3 were measured by 
radioimmnoassay (RIA) of serum samples from using a solid phase RIA (Coat-A-Count, DPC, 
Los Angeles, CA) with between assay and within assay CVs of less than 10%. Estradiol levels 
were measured in visit 3 samples using an alternate fluroimmunometric method (Delfia-Perkin-
Elmer, Fisher Scientific, USA) because of sample volume limitations. Five visit 1 samples were 
reanalyzed with the alternate method and the correlation was strong (r=0.999). Reported 
sensitivity of estradiol and total testosterone assays were between 10-14pg/mL and 4ng/dL 
respectively.  
Serum SHBG levels were determined using an immunoradiometric assay (IRMA) (DSL, 
Webster, TX). This assay has a sensitivity of 3 nmol/L and required only 25µL of sample. 
CHARM III visit 3 specimens were evaluated using an alternate assay because the RIA was no 
longer available. Five specimens collected at visit 1 were reanalyzed using the replacement 
method and there was a strong correlation (r=0.910) between SHBG values using the original  
and replacement  assays. 
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Calculations of the free androgen index (FAI) and free estradiol index (FEI) were made 
using the following formulas, FAI [(100 X TT ng/dL)/(28.84 X SHBG nmol/L)] and FEI [(100 X 
E2 pg/mL)/(272.11 X SHBG nmol/L)]. The ratio of testosterone to estradiol was then 
determined by calculating the ratio of FAI:FEI for each subject (13, 70, 90). 
Lipid, insulin, glucose levels in the fasting blood samples were analyzed by the Heinz 
Nutrition Laboratory at the University of Pittsburgh Graduate School of Public Health according 
to standard methodology (70). Lipid profiles included total cholesterol, high-density lipoprotein 
(HDL), low-density lipoprotein (LDL), and triglycerides. 
 
3.3.2 Homeostatic Model Assessment (HOMA) 
 
Insulin resistance (IR) was estimated using fasting insulin and glucose levels obtained at 
CHARM III clinic visits 1 and 3. HOMA-IR was computed by dividing the product of insulin 
(µIU/mL) and glucose (mg/dL) by 405 (91). 
 
3.3.3 Coronary Artery Calcification 
 
Coronary artery imaging was performed by the Preventive Heart Care Center of the 
University of Pittsburgh Medical Center (UPMC) using an ultrafast CT scanner (Imatron C-150, 
San Francisco, CA). Detailed descriptions of the scanning procedure and calculation of CAC 
score have been published previously (74, 79). Briefly, technicians masked to the case or control 
status obtained thirty to forty 3mm sequential transverse images from root to apex in 100-msec 
exposures at 60% of the R-R interval of the cardiac cycle. Each participant was scanned once at 
each visit to minimize exposure to radiation. Images were analyzed with the AcuImage software 
using a base value region of interest (BVROI) approach. All pixels exceeding an area of 1mm2 
and intensity of 130 Hounsfield units in each 3mm section were considered calcified. 
Calcification scores for each ROI were calculated using the formula (area of all significant pixels 
X grade of peak computerized tomography number); individual ROI scores were then summed 
to arrive at a total CAC score according to the method developed by Agatston et al (92).  
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3.4 Reproductive Variables Created in Present Investigation 
 
 
3.4.1 Reproductive Designations 
 
CHARM III included a detailed reproductive history and a single blood sample for 
reproductive hormones at visits 1 and 3. The investigation was not designed to evaluate the 
menopause transition. To address such a query in women with PCOS a study design 
incorporating more frequent sampling over a greater time span would be optimal. As reviewed 
earlier, the staging criteria for menopause (STRAW) are not reliable in predicting menopause in 
overweight women or those with history of irregular menses (82).  Alternatively, a 
determination of whether the CHARM III participant was menopausal (surgical or natural), not 
menopausal, or unclear (currently using OCs or HRT) was made using a strategy adapted from 
the Women’s Ischemia Syndrome Evaluation (WISE) study algorithm (93). A combination of 
menstrual cycle pattern in the prior twelve months, concurrent use of OCs or HRT, history of 
gynecologic surgery, age, and FSH and E2 levels were used to render a reproductive designation 
for participants at CHARM III visit 1.  
Variability in FSH level is a hallmark of the transition from perimenopause to 
menopause and lab specific cut-offs based on a FSH value great than 2 SD above the mean level 
of FSH in a reproductively competent age group is recommended (82). FSH assay methods were 
unchanged between CHARM I and CHARM III. At CHARM I, the mean FSH levels in a subset of 
cases and controls ages 25-34 years who were not using hormones were 4.6 ± 1.6  and 5.9 ± 4.5 
IU/L, respectively [from unpublished data from thesis dataset (69)]. Thus an FSH cut-off of 20 
IU/L in the context of low E2 (< 50pg/mL) among women in CHARM III is conservative for 
those who reported that their cycles had stopped or who had undergone a hysterectomy.  
Women who reported 5 or more months of amenorrhea prior to visit 1 and who had not 
had a hysterectomy were considered menopausal if they had an FSH level greater than 20 IU/L 
and estradiol level less than 50 pg/mL when not using hormone replacement. Similarly, women 
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who had previously undergone hysterectomy with one or both ovaries intact were considered 
definitely menopausal if they had an FSH ≥20 IU/L and E2 ≤50pg/mL and were not currently 
using HRT or OCs. This group was designated as natural menopause. 
Menopause status was also assigned to any woman with a history of a bilateral salpingo-
oophorectomy (BSO) or chemotherapeutic treatment resulting in ovarian toxicity. Women with 
a spontaneous cessation of menses prior to age 40 and elevated FSH (≥20 IU/L) and low 
estradiol (≤50 pg/mL) were considered to have premature ovarian failure. These presentations 
were treated as a separate menopause group. 
Women reporting a regular menstrual cycle or less than 5 months of amenorrhea were 
classified as not menopausal. Those women who previously underwent a hysterectomy and were 
not using hormones and had an FSH level <20IU/L were considered not menopausal.  
The remaining subjects reporting current HRT use were classified as menopausal if they 
reported that their menses had stopped before starting HRT. Exogenous hormones mask 
underlying menstrual cycle pattern and endogenous hormone levels. Oral contraceptives have 
been shown to suppress LH and FSH levels in young women and young women with PCOS (39, 
94). Likewise, Dupont et al showed that HRT suppressed LH and FSH in postmenopausal 
women however, levels remained higher than in premenopausal women (95). Further, women 
with a previous BSO and were placed on daily HRT for 12 months had mean (SD) FSH levels of 
84.7 (31.1) IU/L (96). Similarly FSH was not suppressed to premenopausal levels in a 
Norwegian cohort of postmenopausal women using HRT (97). For these reasons and because 
our questionnaire captured timing of initiation of hormone replacement, a presumptive 
designation of reproductive status was made for women on HRT or OCs based on endogenous 
hormone levels and menstrual history.  We approached the inclusion of these subjects 
conservatively in our analysis by conducting statistical evaluations with and without these 
subjects in our models.  
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A small number of cases and controls using HRT or OCs could not be classified because 
of equivocal hormone levels or use of HRT prior to spontaneous cessation of menses. These 
women were classified as unclear.   One participant had amenorrhea for > 12 months and was 
not using HRT or OCs, exhibited hormonal pattern consistent with hypothalamic 
hypogonadism. This participant was currently using gabapentin which has been shown to be 
effective for managing hot flashes (98). Studies in male rats have shown that gabapentin 
suppresses FSH and testosterone levels and reduces fertility (99). This participant was also 
classified as unclear. 
 
3.4.2 Duration of Menopause 
 
The duration of menopause was calculated from the age at which a participant reported 
their period had stopped to age at study visit. This measure could not be determined for women 
who underwent a hysterectomy without bilateral oophorectomy because the study was not 
designed to include a sampling frequency to assess biochemical markers of ovarian function in 
the absence of menses. Based on recent guidelines from the follow-up to STRAW (STRAW +10) 
where rationale for categorizing the post menopause by duration in consideration of continued 
physiologic changes including rising to FSH and diminishing estradiol levels and symptoms of 
estrogen deficiency such as vaginal and urogenital complaints (100) a grouping variable based 
on duration was created for menopausal women in CHARM. Categories were based on the 
recommendations from the follow-up report from the Stages of Reproductive Aging Workshop,  
≤2 years, 2-6 years, and >6 years since final menstrual period(100). When possible, suspected 
timing of menopause was determined for women who had previously undergone hysterectomy 
based on timing between surgery and age at CHARM III visit 1. 
 
3.4.3 Lifetime Cycle Irregularity 
 
Women with PCOS report varying degrees of menstrual irregularity that could overtime 
translate to differential exposures to sex steroids and thus influence CVD risk factors or 
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subclinical marker of CDV. Women participating in CHARM III visit 1 were asked to estimate 
the number and duration of cycles they had per year during each decade from the teens through 
current decade when not using hormonal contraception or pregnant. They were also queried 
about hormone use and birth of children across each decade. This information was used to 
devise a metric for overall menstrual irregularity. The steps to quantify lifetime irregularity are 
outline below.   
1) Total reproductive years 
a. The difference between the participant’s current age or age at menopause and age 
at first menses.  
b. This number was then subdivided by decade to determine the number of 
reproductive years contributed during the teens, 20s, 30s, and 40s.    
2) Number of natural cycles per decade 
a. This figure was determined by multiplying the number of periods per year when 
not pregnant or on oral contraceptives by the number of reproductive years 
contributed in the decade.  
3) Cumulative natural cycle number 
a. The total number of natural cycles was calculated as the sum of cycles 
contributed in each decade. 
4) Live birth and oral contraceptive adjustment 
a. Pregnancy is associated with a significant increase in estradiol 2.5 ng/mL in the 
first trimester to 15 ng/mL by the time of delivery (101), thus any pregnancy 
resulting in a live birth was assigned 10 cycles and added to the cumulative cycle 
number. Multiple gestations were treated as one pregnancy. 
b. OCs effectively suppress androgen levels (39, 94) in women with PCOS and do 
not appear to have a negative effect on metabolic parameters (94, 102). Thus the 
duration of OC use reported was added to the cumulative cycle number.   
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5) Lifetime irregularity 
a. Overall lifetime irregularity reflects the combined contributions of natural cycles, 
pregnancy, and OC use.  
b. To account for differences in ages, total lifetime irregularity was divided by the 
total reproductive years contributed.   
The approach for calculating lifetime cycle irregularity is outlined in Table 3 and includes an 
examples based on an actual case.   
 
 
3.5 Statistical Analyses 
 
3.5.1 Specific Aim 1 
 
Specific Aim 1: examine the association between menopause and CVD risk factors and CAC in 
women with a history of PCOS and controls adjusting for age, body mass index, as well as other 
known predictors of CVD risk factors. 
Hypothesis 1: menopause will further exacerbate risk factors for CVD and subclinical 
atherosclerosis (SCA) in older women with a history of PCOS compared to controls. 
Descriptive analyses were completed and univariate assessments of differences at 
CHARM III visit 1 between combined cases and controls as well as cases and controls in four age 
and four reproductive strata were performed. Mann-Whitney U-test was used to evaluate 
differences in continuous variables between cases and controls within each strata. Kruskal-
Wallis was then used to examine differences in outcome measures within cases or controls 
across strata. The χ2 test was used to evaluate differences in categorical measures.   
To evaluate potential interaction effects between PCOS status and reproductive status on 
CVD risk factors a two-way analysis of variance (ANOVA) was conducted. The effect of control 
or case (PCOS) status on the risk factor was examined across three reproductive strata (non-
menopausal, natural menopause, and surgical menopause). A p value of <0.05 was considered 
significant. 
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Multiple linear regression models were constructed to examine the effect of case or 
control status on cardiovascular risk factors adjusting for type of menopause, age, and body 
mass index. Models were created by evaluating the effect of PCOS status on the risk factor of 
interest and then introducing each covariate into the model. To examine the relationship 
between natural or surgical menopause and PCOS on the risk factor, separate dummy variables 
were created for natural and surgical menopause and the interaction between these variables 
and PCOS. Non-normally distributed variables were log transformed before being entered into 
the models.   
CAC was highly skewed; most participants had values with Agatson Scores at or very 
near zero. A dichotomous variable for CAC (<10 or ≥ 10 Agaston Score) was created and logistic 
regression used to evaluate predictors of CAC among cases and controls. An interaction term for 
PCOS and menopause was included in these models.  
Based on previous experience with this cohort it was known that age differed between 
cases and controls. A subset of sequentially age ± one year and ethnicity matched cases and 
controls was created from the CHARM III visit 1 participant cohort. To avoid potential 
confounding effects of hormone use and premature menopause, cases and controls currently 
using OCs or HRT preparations or who had undergone pelvic surgery and experienced a 
cessation of menses or who experienced premature or medical menopause were excluded.  The 
matched subset was similarly evaluated to determine if there was a difference in the occurrence 
of natural menopause between cases and controls. 
 
3.5.2 Specific Aim 2 
 
Specific Aim 2: examine the association between degree of menstrual irregularity, determined 
by number of cycles reported across earlier reproductive years, and CVD risk factors and CAC 
among women with PCOS who were evaluated during later reproductive to menopausal years. 
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Hypothesis 2: greater menstrual irregularity across time will be associated with a more 
adverse CVD risk profile and SCA documented by CAC in women with a history of PCOS. 
Between and within subject comparisons for the change over time in the number of 
cycles during each decade were evaluated using a repeated measures analysis of variance. Cases 
were stratified based on degree of cycle irregularity (< 9 cycles/year, 9-11 cycles/year, and more 
than 11 cycles/year) and the Kruskal-Wallis test was used to evaluate univariate differences 
between PCOS cases by degree of cycle irregularity. Chi square was used to evaluate differences 
in categorical outcomes. Logistic regression models were constructed to evaluate the effect of 
cycle irregularity adjusting for other predictors on the presence of CAC among cases.  
 
3.5.3 Specific Aim 3 
 
Specific Aim 3: examine the relationship between ovarian reserve, documented by anti-
müllerian hormone (AMH) level and relative testosterone to estradiol ratio, documented by the 
ratio of free androgen index to free estradiol index (FAI/FEI) in late reproductive age women 
with PCOS compared to controls. 
Hypothesis 3: decreases in AMH level will be associated with an increased FAI/FEI ratio in 
both PCOS and controls. PCOS will have a smaller change in FAI/FEI that correlates with a 
higher AMH level. 
Cases and controls were sequentially matched based on age at CHARM III visit 1. A 
repeated measures analysis of variance was used to evaluate potential differences in the 
parameters of age and BMI from visit 1 to visit 3 within and between subjects. Differences in the 
proportion of women in each group reporting cycles and using hormones between visit 1 and 
visit 3 were evaluated using McNemar’s test. Percent change relative to the baseline ([(V3 –
V1)/V1 ]*100) was computed for each outcome variable. Comparisons were conducted using 
Mann Whitney test. Spearman correlations were used to examine potential relationships 
between change in AMH and FAI/FEI between visits within cases and controls.  
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CHARM III Visit 1
N=321
Cases
N=152
Controls
N=169
Interview 
n=152
Bloods 
n=151
Anthro
n=152
CAC
n=149
CAC
n=168
Anthro
n=169
Bloods 
n=168
Interview 
n=169
CHARM III Visit 3
N=121
CHARM III Visit 3
N=154
AMH-Hormones-Interview
N=37
AMH-Hormones-Interview
N=40
3.6 Figures and Tables for Section 3.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Anthro: Anthropomorphic Measurements 
CAC: Coronary Artery Calcification  
AMH: Antimüllerian Hormone 
 
 
Figure 1. Phases of the Cardiovascular Health and Risk Measurement (CHARM) III Study 
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Table 3. Lifetime cycle irregularity calculations 
Step Calculation 
Example 1-Case Example 2-control 
Current Age: 52, Menarche: 12, Cycling: 
Yes 
Current Age: 52, Menarche: 12, Cycling: 
Yes 
OCs: 60 months during 30s OCs: 60 months during 30s 
Live Births: 3 total (2 during 20s; 1 during 
30s) 
Live Births: 3 total (2 during 20s; 1 during 
30s) 
1)  
    
Reproductive 
Years 
Age at visit (or menopause) 
– Age at menarche 52 - 12 = 40yrs 52-12 = 40 yrs 
2)  
    
Number of Natural 
Cycles/ decade 
Periods/year (PPY) X 
number reproductive years/ 
decade 
Decade Repro 
yrs 
PPY Natural 
Cycles 
Decade Repro 
yrs 
PPY Natural 
Cycles 
Teens 8 6 48 Teens 8 10 80 
20s 8.3 5 41.5 20s 8.3 12 99.6 
30s 4.2 5 20.8 30s 4.2 12 50 
40s 10 10 100 40s 10 12 120 
3)  
    
Cumulative 
Natural Cycles 
Natural cycles teens + 20s 
+ 30s + 40s 210.3 cycles 349.6 cycles 
4)  
    
Live births Pregnancies resulting in 
live births X 10 months 30 cycles 30 cycles 
5)  
    
Oral 
contraceptives 
Months of OC Use teens + 
20s + 30s + 40s 60 cycles 60 cycles 
6)  
    
Adjusted lifetime 
cycle number 
Cumulative natural cycles + 
Pregnancy Months + OC 
months 
300.3 cycles 439.6 cycles 
7)  
    
Adjusted lifetime 
cycles/ 
reproductive year 
Lifetime irregularity/total 
reproductive years 7.5 cycles/yr 11 cycles/yr 
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4.0 RESULTS 
 
 
4.1 Aim 1 
 
CHARM III, visit 1 included a total of 321 subjects (152 PCOS cases and 169 controls) age 
35 years or greater. Subjects were predominantly Caucasian and educated beyond the twelfth 
grade, Table 4a. Cases were statistically significantly younger (mean ± SD) than controls (47.2 
± 5.6 vs. 49.5 ± 5.9, Mann-Whitney U-test p<0.001) (Figure 2). Because the age distribution of 
cases and controls differed, four age strata were created: 1) less than age 45 years, 2) ages 45-49 
years, 3) ages 50-54 years, and 4) age 55 years or greater. Subject characteristics and outcomes 
presented in Tables 4a (baseline characteristics), 4b (metabolic outcomes), and 4c 
(reproductive parameters) include all cases and controls  and subjects stratified by age group. 
Cases were more obese with greater central adiposity (waist to hip ratio) compared to controls, 
Table 4a. When stratified by age group, cases younger than age 55 years showed significantly 
higher BMI and waist to hip ratio compared to controls.  
Comparable numbers of women reported use of statins in both the case and control 
groups, Table 4a. More cases were using diabetes medications 10.3% compared to controls 
3.9%, χ2 p=0.035.  Due to small numbers this difference was no longer significant when 
stratified by age.  Cases in the youngest age strata (<45 years) had somewhat higher use 21.3% of 
anti-hypertensive medications compared to controls in the same age strata 6.3%, χ2 p=0.068. 
This difference was no longer apparent in older age strata. There were significant numbers of 
missing observations for use of antihypertensive (n=112 cases; 108 controls), diabetes 
(metformin) (n=107 cases; 101 controls), and insulin (n=101 cases; 101 controls) medications in 
the CHARM III, visit 1 dataset. 
As shown in Table 4b, cases had lower total HDL and higher triglyceride and insulin 
levels relative to controls. Type 2 diabetes, as defined by self-reported history or fasting glucose 
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≥ 126 mg/dL, was three times more prevalent in cases compared to controls (12.5% vs. 3.6%, 
p<0.01) and insulin resistance (HOMA-IR) was also significantly greater in PCOS compared to 
controls (p<0.001). Differences in risk factors for cardiovascular disease and diabetes persisted 
between the cases and controls of the intermediate age groups (45-54 years). Diabetes remained 
significantly higher among the cases 45 years and older. When stratified by age cases exhibited a 
greater degree of insulin resistance at ages less than 55 years. Cases had greater coronary artery 
calcification scores in all age groups compared to controls and the difference was most evident 
between cases and controls in the two older age strata, Table 4b.   
While the average age of cases and controls in the 50-54 year age group was comparable, 
a greater proportion of controls reported natural menopause 42.2% compared to 22.2% of cases 
(p<0.05), Table 4a.  However, in women over 55 years the reverse was noted. At CHARM III 
visit 1 cases generally fit the typical hormonal profile observed in earlier CHARM studies; higher 
LH:FSH ratio and total testosterone level and lower SHBG level compared to controls, Table 
4c.  When stratified by age older cases consistently exhibited significantly lower LH and FSH 
levels compared to control counterparts.  TT was significantly higher in cases compared to 
controls in the youngest age strata and comparable between cases and controls at ages greater 
than 45 years.  SHBG was lower in cases of the two youngest strata but comparable in women 50 
years and older.  Estradiol did not differ between cases and control at any age. The free 
androgen index was statistically significantly higher in cases compared to controls in all strata. 
The free estradiol index was higher in cases compared to controls less than 50 years of age and 
decreased with age and was similar levels between cases and controls >55 years. FAI to FEI ratio 
differed between combined cases and controls. However, the difference was no longer 
significant when stratified by age. The FAI:FEI ratio rose across age strata for cases and controls 
and was comparable for cases and controls >55 years, however this trend did not reach the level 
of statistical significance.  
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A significant positive correlation between HOMA-IR and BMI was observed in both 
cases and controls (Spearman r2=0.450, p<0.001). SHBG level was significantly and inversely 
correlated with HOMA-IR (Spearman r2=-0.279, p<0.001) and BMI (Spearman r2=-0.434, 
p<0.001). No statistically significant correlation between FSH level and BMI (Spearman r2=-
0.034, p=0.623) or insulin resistance (Spearman r2=-0.008, p=0.924) was observed among 
cases. 
At CHARM III visit 1, forty-five (30%) cases and seventy-nine (47%) controls reported 
that their menstrual cycles had stopped. Twenty-two (49%) cases and thirty-four (43%) controls 
reported either hysterectomy with or without bilateral oophorectomy as the reason for their 
periods stopping. Figure 3 depicts the various reasons for cessation of menses in cases and 
controls. Twenty-two cases (14.5%) and thirty-four controls (20.4%) reported having a 
hysterectomy with or without a BSO or unspecified uterine/ovarian surgery associated with the 
cessation of their menstrual cycles. There was no difference in the proportion of participants 
having hysterectomy between cases and controls, χ2 p=0.168. Participants at CHARM III visit 1 
were classified as not menopausal (96 cases and 79 controls), menopausal (19 cases and 38 
controls), surgical menopause (11 cases and 17 controls), or unclear (25 cases and 33 controls), 
Figure 4. 
Cases and controls were similar with regard to age at first menses, number of 
pregnancies, and OC use but cases were more likely to have used fertility medications and had 
fewer live births compared to controls, Table 5. The average duration of surgical menopause 
was significantly longer than natural menopause (108.4 (98.4) months vs. 60.2 (50.7) months, 
Mann-Whitney p=0.037) in all participants.  The mean (SD) duration of natural menopause was 
similar for cases 61.5 (58.5) months and controls 59.7 (48.3) (Mann-Whitney p=0.945), not 
shown in Table 5.  Likewise the duration of surgical menopause did not differ between cases and 
controls (134.0 (148.2) months vs. 97.1 (70.6) months, Mann-Whitney p = 0.894). Menopause 
duration could not be computed for women who stopped menstruating due to hysterectomy 
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without bilateral oophorectomy or who did not provide information on when their cycle 
stopped.  
Within the unclear group of 25 cases and 34 controls, a presumptive determination of 
menopause or not was made for 17 cases and 25 controls.  We conducted our analysis with and 
without these subjects and our findings were statistically comparable. The results presented in 
Tables 6-8 include these subjects. Tables 6a and 6b, provide an overview of subject 
characteristics stratified by menopause status. Menopausal cases and controls were about ten 
years older than cases and controls who were not menopausal. Age was comparable within the 
non-menopausal and natural menopausal strata, but cases were who had surgical menopause 
were slightly younger than controls with surgical menopause but the difference did not reach 
statistical significance. Ages differed significantly across reproductive groups (ANOVA 
p<0.001). Post hoc testing with a Bonferroni correction identified that women who were 
classified as not menopausal were significantly younger than the natural, surgical and unknown 
groups (p<0.001). Women with surgical menopause were significantly younger than those with 
natural menopause (p<0.001) and comparable to the unknown group.  
Cases who were not menopausal or who had natural menopause were more obese and 
had increased central adiposity compared to controls. Cases designated as not menopausal had 
significantly higher SBP and somewhat higher DBP compared to control counterparts. In 
addition, cases who were not menopausal had higher triglyceride and lower HDL levels 
compared to controls. Menopausal cases and controls had comparable blood pressures, HDL, 
and LDL levels.  Triglyceride levels did not differ significantly but cases reporting natural 
menopause had a median triglyceride levels 10 points higher than control counterparts. Cases 
who were not menopausal as well as cases in the natural and surgical menopause groups had 
increased insulin resistance and insulin levels compared to controls. Most striking was that 
25.0% of cases with natural menopausal had type 2 diabetes versus 1.9% of controls (p<0.01). 
Evidence of CAC was also significantly higher in both non-menopausal and menopausal cases 
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compared to controls. Significantly more cases in both the menopausal and not menopausal 
groups exhibited CAC exceeding 10 Agatston units compared to controls, Table 6a.   
The ratio of LH to FSH, total testosterone level, FAI, FEI, and FAI:FEI were higher and 
SHBG level was lower in cases who were not menopausal compared to controls who were not 
menopausal (Table 6b). LH and FSH levels were significantly lower in menopausal cases 
compared to controls. Estradiol, and testosterone levels were comparable but FAI and FEI were 
significantly greater in cases compared to controls that had natural menopause. This can be 
attributed to the significantly lower levels of SHBG observed the cases with natural menopause.  
The median FAI was higher and median SHBG level lower in cases with surgical menopause 
compared to controls with surgical menopause but the differences did not reach statistical 
significance. 
A factorial ANOVA showed no significant effect of group (p=0.251) but a significant 
effect of reproductive status (p=0.028), with no interaction (p=0.765) on SBP. Neither group 
(p=0.184) nor reproductive status (p=0.719) had any effect on HDL cholesterol level, nor was 
there a significant interaction (p=0.685). Triglycerides were associated with significant effects 
for both group (p=0.021) and reproductive status (p=0.009) and were non-significant for 
interaction (p=0.844). Figure 5 shows the relationships between group (control or PCOS case) 
and reproductive status (not menopausal, natural menopause, or surgical menopause) on 
systolic blood pressure, HDL cholesterol, and triglycerides.  Triglyceride levels were log 
transformed for the analysis.  
Parameters from multiple linear regression models are shown in Table 7 and after 
adjusting for age and BMI, PCOS status was not predictive of SBP or HDL but was a predictor of 
triglyceride level. Neither surgical nor natural menopause predicted SBP or HDL added any 
further impact to the risk of increased SBP or decreased HDL when included with age, BMI, and 
PCOS.  However, surgical menopause was significantly associated with increased triglyceride 
levels.  The effect of hormone used however negated the effect of surgical menopause on 
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triglycerides. Hormone use was also positively associated with HDL when modeled with age, 
BMI, PCOS status and menopause. Older age and increased BMI were predictive of SBP. BMI 
was most predictive of lower HDL level and higher triglyceride level. Because SHBG, HOMA-IR 
and BMI are inter-related and highly correlated with PCOS status these variables were not used 
as separate predictors in the regression models. There was no interaction effect of PCOS and any 
type of menopause in the models tested. 
Logistic regression was performed to evaluate predictors of CAC score of ten or greater.  
As shown in Table 8, PCOS remained a significant predictor of increased CAC score (2.385, 
95% CI 1.195, 4.762, p = 0.014) when menopause type, BMI, and age were included in the 
model. Natural menopause was also predictive of a CAC greater than 10 (4.579, 95% CI 1.599, 
13.060, p=0.005).  
The matched subset included 83 cases and controls.  Eleven (13%) of the pairs were 
African American. As a group, cases were heavier with greater central adiposity compared to 
controls, Table 9. The proportion of cases and controls who had experienced natural 
menopause was not statistically different (18.1% vs. 27.7%, χ2 p = 0.192) and the duration of 
menopause was similar between cases (61.5 ± 58.5 months) and controls (60.5 ± 50.4 months), 
Mann-Whitney p=0.943.  Cases and controls in this age matched subset were comparable in age 
and in proportion and duration of menopause.  Other outcomes between the two groups were 
comparable to those observed in the larger cohort, Tables 10 and 11. 
 
 
4.2 Aim 2 
 
We next evaluated whether degree of menstrual irregularity at younger ages was 
predictive of CVD risk factors among older women with PCOS.  The average number of natural 
cycles per year at each decade was significantly lower for cases compared to controls RM 
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ANOVA p=0.042, but increased similarly across each decade from the 20s RM ANOVA 
p<0.001, Figure 6.  The median (IQR) of natural cycles at each decade is shown in Table 12.    
Cases with the fewest cycles over time had higher total testosterone, FAI, and FAI to FEI 
ratio compared to cases with more frequent cycles, Table 13. There were no differences in CVD 
risk factors, prevalence of diabetes or % CAC between cycle groups. Subjects with the greatest 
degree of irregularity had higher total average CAC scores compared to those cases with less 
irregularity, however there was not a statistically significant difference between groups. 
When evaluated in a logistic regression model, the greater cycle irregularity did not 
predict greater CAC when adjusting for age and insulin resistance, Table 14.  
 
 
4.3 Aim 3 
 
 
A total of 28 cases and 28 sequentially age ± 1 year matched controls were included in 
Aim 3.  Subjects were between the ages of 42 and 48 years at CHARM III visit 1, not 
menopausal, and were not currently using OCs or HRT.  As depicted in Table 15, the percent 
change in age from visit 1 to visit 3 was comparable between cases (6.8%) and controls (6.3%) 
(Mann-Whitney p=0.43).  A repeated measures ANOVA documented that cases and controls 
were comparable in age (p=0.29) at each visit and increased similarly between visit 1 and visit 3 
(p<0.001).  Further, cases and controls did not experience significant differences in percent 
weight loss or weight gain between visit 1 and visit 3 (Mann-Whitney p=0.93).  Further, BMI 
was comparable between cases and controls (Repeated Measures ANOVA p=0.51) and across 
each visit (Repeated Measures ANOVA p=0.88). 
The proportion of cases reporting cycles did not change significantly between V1(96.4%) 
and V3 (82.1%) (McNemar p=0.125). Similarly, there was not a statistically significant change in 
among controls reporting cycles from visit 1 (96.4%) to visit 3 (85.7%)  (McNemar p=0.250).  
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Hormone profiles including AMH levels for this subset women appear in Table 15.  
There was a statistically significant difference between cases and controls for change in AMH 
level across the visits.  However, AMH level was near the limit of detectability for the assay.    
A Spearman’s correlation was used to determine associations between biochemical 
markers evaluated at visit 1 and changes in biochemical markers evaluated at visit 1 and visit 3 
in cases and controls.  An inverse association between age and AMH level was observed in cases 
(rs=-0.442, p=0.018) and controls (r2=-0.483, p=0.009) at visit 1. Similarly, AMH and FSH 
were inversely associated at the initial visit in controls (rs=-0.426, p=0.024) but not cases (rs=-
0.248, p=0.203). There was no association between change in AMH between visits and change 
in FSH, androgens, estradiol or SHGB level in either cases or controls.  However, change in BMI 
among cases was directly correlated with change in insulin resistance (rs=0.424, p=0.031) and 
inversely correlated with change in SHBG level (rs=-0.485, p=0.010).  Further, BMI change was 
positively associated with change in FAI (rs=0.410, p=0.034) and FEI (rs=0.407, p=0.035).  An 
inverse association between change in BMI and change in HDL was also observed (rs=-0.395, 
p=0.037). 
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5.0   CONCLUSIONS 
 
 
Our overall objective was to examine the relationship between reproductive status and 
menstrual irregularity on CVD risk factors and sub-clinical atherosclerosis in women with a 
history of PCOS and normal reproductive control subjects.  The study population was initially 
described in 1993-1994 when the cases and controls were on average in their mid- to late 
thirties.  At CHARM III, about ten years later, those women enrolled as PCOS cases exhibited a 
presentation consistent with the reproductive, endocrine and metabolic profile generally 
ascribed to the condition i.e., irregular periods, high LH to FSH ratio, increased androgens, 
insulin resistance, and CVD risk factors.  When stratified by age or menopause, only younger 
cases (ages 45-49) were observed to have a more consistently adverse CVD risk profile compared 
to controls as evidenced by greater obesity and central adiposity, higher SBP and triglyceride 
levels, and lower HDL.  Differences in BMI and WHR between cases and controls persisted in 
cases with natural menopause but not in cases with surgical menopause.  Blood pressure and 
lipid levels were comparable between menopausal cases and controls.   
Multiple linear regression models showed that neither history of PCOS or menopause 
status predicted an increase in SBP or decrease in HDL when adjusting for age or BMI. This 
suggests that the independent contribution of PCOS to CVD risk profile observed between 
younger cases and controls in CHARM diminishes with increasing age.  
Overall 12.5% of cases compared to 3.6% of controls had type 2 diabetes. Menopausal 
cases exhibited significantly greater type 2 diabetes than younger or control counter parts. 
According to the CDC, 10.4% of white females between the ages of 45-64 have diabetes whereas 
18.9% of black females in this age range have diabetes. These percentages increase to 16.9% and 
31.2% respectively in women ages 65-74 (103). At CHARM III visit 1, 25.0% (n=6) cases with 
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natural menopause had diabetes. Another 28.6% (n=4) cases who reported surgical menopause 
were also diabetic. Nine of these 10 women were white and all were younger than 65 years. 
Thus, in CHARM III we observed diabetes prevalence rates more than twice that of the general 
female population. The rates of diabetes in white menopausal women with a history of PCOS 
were on the order of those observed among older black women. These findings coexist with a 
decrease in SHBG level in cases relative to controls. A recent review by Le et al, summarized 
available data including genetic evidence on the associations between low SHBG and risk for 
type 2 diabetes and suggests that SHBG is a biomarker for elevated insulin and glucose (104). In 
the CHARM III visit 1 data set HOMA-IR and BMI were significantly positively correlated in 
cases and controls (Spearman r2=0.450, p<0.001). SHBG level was significantly and inversely 
correlated with HOMA-IR (Spearman r2=-0.279, p<0.001) and BMI (Spearman r2=-0.434, 
p<0.001).  
We also observed significantly lower levels of gonadotropins (FSH) in menopausal PCOS 
compared to controls. There is evidence that at least 25% of men with type 2 diabetes have 
hypothalamic hypogonadism which is characterized by very low LH and FSH and accompanying 
low levels of free testosterone (105). Further, obesity in women has been associated with lower 
levels (106). No statistically significant correlation between FSH level and BMI (Spearman r2=-
0.034, p=0.623) or insulin resistance (Spearman r2=-0.008, p=0.924) was observed among 
cases and this is likely due to the wide variation in FSH across the two groups. However, among 
women with natural menopause FSH levels were significantly inversely correlated with BMI 
(rs=-0.527, p=0.001) and insulin resistance (rs=-0.535, p=0.001).  When evaluated separately, 
this relationship held within controls and cases who had undergone natural menopause.   
Compared to controls, cases who had natural menopause recorded significantly higher 
estradiol levels that could also contribute to FSH suppression. However, there was not a 
statistically significant correlation between FSH and estradiol.   
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While CVD risk factors did not appear to worsen in menopausal women with a history of 
PCOS after adjusting for age, BMI, and hormone use, there was evidence of that subclinical 
atherosclerosis as measured by CAC was influenced by PCOS status and menopause 
independent of age and BMI. CAC was greater in PCOS compared to controls and this increase 
in subclinical atherosclerosis was most evident in the middle and older age strata. The odds of 
having a CAC score greater than ten were about 2 times higher in women with a history of PCOS 
compared to controls and 4.5 times higher following natural menopause when compared to non-
menopausal controls. This relationship was preserved even after including age and BMI and is 
consistent with earlier reports by Talbott et al (79). However, the relationship between CAC and 
surgical menopause was not observed in PCOS cases in this evaluation and that may have to do 
with how the reproductive status was defined. In particular, women using HRT were classified 
as unclear and these women as a group had healthier profiles and lower CAC (Table 6a) and 
may have been included in the 2008 report as menopausal.  Additionally, women with 
hysterectomy and intact ovaries were not classified as surgical menopause in this current 
analysis but may have been part of the surgical designation of the prior analysis. An evaluation 
of discordant group assignments will be necessary to clarify this discrepancy.  
We found no differences in CVD risk factors or CAC in an older group of women with a 
history of PCOS stratified by degree of lifetime menstrual irregularity. More irregular (less 
frequent) cycles were associated with statistically significantly higher total and free androgen 
levels and FAI to FEI ratio.  Logistic regression did not reveal that degree of cycle irregularity in 
cases across time was associated with an increased odds of CAC greater than 10 when age and 
insulin resistance were included in the model.  The association between CAC and insulin 
resistance is not surprising; the observation that 25-29% of postmenopausal cases have type 2 
diabetes supports the importance of diabetes prevention measures being introduced early for 
women with a prior history of PCOS approaching menopause.   
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The exploratory aim identified a statistically significant change in AMH level between 
the two CHARM III visits among PCOS cases.  AMH levels in PCOS cases at visit 3 were 
comparable to AMH level of controls at visit 1.  Caution is needed when evaluating any 
significance of this result due to the younger age of the PCOS group.  Also, levels of androgen 
hormones and estradiol were near the assays’ detect limits. Other metrics examined did not 
differ between cases and controls and that could be due to a small sample size. However, we did 
find significant correlations between changes in BMI and CVD risk factors and insulin resistance 
in this small group of women.  These data combined with the findings of greater type 2 diabetes 
in PCOS following menopause suggest that perimenopausal weight gain could trigger transition 
from insulin resistance to diabetes and further progression of CVD RF and subclinical 
atherosclerosis. However, in the cross-sectional evaluation of the large group at CHARM III visit 
1, BMI was comparable between non-menopausal and menopausal cases (Table 6a).  Given the 
small sample size and significance of the findings a re-evaluation and expansion of the sample 
size would be a compelling effort. The limitation for this aim was related to having only a small 
number of subjects with specimens available for measurement of reproductive hormones. 
However, metabolic indicators, lipids, medical and reproductive histories were collected on all 
subjects and could be expanded to strengthen the analysis.  
Many women in both the case and control group reported that they used OCs or 
medroxyprogesterone acetate (MPA/Provera) for contraception or menstrual cycle regulation.  
It is conceivable that the androgen suppressive effects of oral contraceptives may have had a 
positive effect on CVD risk profiles in older PCOS cases. There is evidence that OCs do not 
worsen CVD risk factors.  The use of combined OCs in young eumenorrheic controls (n=10) and 
PCOS cases (n=9) was associated with decreased insulin sensitivity in both groups and an 
increase in triglyceride levels of only the controls(94).  Cholesterol and HDL were comparable 
between controls and PCOS at baseline and after 3 months of continuous OC administration 
(94). Further, a recent meta-analysis examined the literature for associations between combined 
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OCs and metabolic indicators in women with PCOS from 35 different studies.  Overall OCs 
increased HDLc and triglyceride levels significantly and there were no significant changes in 
LDLc, total cholesterol, insulin or glucose (102). 
  
5.1 Study Limitations 
 
Certainly the age difference between cases and controls presented a challenge 
particularly when attempting to evaluate the contribution of an age related reproductive 
processes to cardiovascular risk. We evaluated this in a small subset of age matched cases and 
controls (83 per group) and found no differences in the proportion of subject who were 
menopausal. A much larger sample size and a different study design would be needed to fully 
compare the menopause transition between cases and controls.  Also, the cases and controls in 
this study were largely white and well educated.  In addition, cases were identified from an 
infertility practice and as such may have had a different course due to earlier interventions. For 
these reasons, our finding may not be generalizable to a larger more diverse population. 
There are a few studies where lifetime estrogen exposure has been attempted. Each 
touches on the challenges of recall bias and reporting of cycle history and hormone use.  
CHARM is no different.  Lifetime cycle irregularity was shown to be associated with higher 
androgen levels at CHARM III visit 1. The study does not permit evaluation of 
hormone/androgen exposure over time.  These measures are also subject to recall bias and may 
not be the most accurate reflection of estrogen exposure across time particularly in women with 
irregular menses.  Moreover, menstrual bleeding is not verification of ovulation and in this 
study could be an over estimate of what could be a normal estrogen exposure.  An exercise to 
examine consistency of a subjects’ recall across the three CHARM phases would be to evaluate in 
a subset of cases and controls individual responses to questions pertaining to cycle frequency 
and cycle duration that were provided at each clinical interview during phases I, II, and III for 
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the same decades. Other challenges to deriving this number is that information on breastfeeding 
and lactational amenorrhea was not obtained nor was information on specific type of HRT 
consistently obtained.  
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6.0 FUTURE DIRECTIONS 
 
 
While the definition and classification of PCOS continues to be debated, we know that 
the clinical presentation of menstrual irregularity in the context of ovarian hyperandrogenism 
and metabolic syndrome places a woman at increased risk for long term negative health 
consequences. We were not able to determine the trajectory of ovarian senescence in our study 
nor do the findings presented here suggest that menopause independent of age further amplifies 
cardiovascular disease risk factors in women with a history of PCOS. However, our finding do 
support the notion that when type 2 diabetes manifests in older women with a history of PCOS 
there is increased evidence of early atherosclerosis. In this study the participants were relatively 
young and had generally managed their PCOS symptoms for decades beginning with their 
presentation for infertility evaluation. The majority had a primary physician, carried a 
pregnancy to term, and when not desiring pregnancy controlled their menstrual symptoms with 
oral contraceptives or MPA. Longer duration of follow-up of the women in the Pittsburgh 
CHARM cohort will be necessary to more completely characterize the postmenopausal disease 
burden associated with a history of PCOS. 
 
6.1 Determining the Menopause Phenotype of PCOS 
 
A research priority set by the ASRM/ESHRE is to define the menopause phenotype of 
PCOS(12). The participants of CHARM have been well characterized during the middle to late 
reproductive years. Our data suggests the type 2 diabetes is a predominant feature among 
postmenopausal women with a history of PCOS.  Today in 2012 the average age of the women 
seen at CHARM III visit 1 would between 57 and 59 years. This middle to late postmenopausal 
age range (100) represents an ideal population to address this knowledge gap. A study to 
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evaluate hormonal and metabolic features, associated sequelae including of cardio- and 
cerebrovascular events, as well as evaluations of menopause quality of life and pelvic floor 
disorders or presence of urogynecologic symptoms that are associated with aging, diabetes, and 
obesity would provide a profile of PCOS in the postmenopausal woman. A follow-up study in 
this well characterized cohort would shed new insights on the long-term health risks and 
experiences of older women with the condition that could inform practitioners on appropriate 
management strategies to guard against these risks.  
 
6.2 Knowledge, Attitudes, and Practices in Approaching the PCOS Patient 
 
Cyclic menstrual function and ovulation are indicators of a woman’s overall  health. 
While PCOS becomes evident at menarche and manifests throughout a woman’s reproductive 
life, the underlying metabolic features associated with the condition may be silent and not be the 
first consideration when seeking or administering care. The American College of Obstetricians 
and Gynecologists released new practice guidelines in 2009 for the clinical management of the 
PCOS patient that encourage providers to follow Level A recommendations focused on 
behavioral management for metabolic risks (5). However, it is unclear whether there is uptake 
among U.S. providers and if there are adequate systems and referral networks to provide 
supportive interventions for this high risk population aimed at mitigating risks of metabolic 
syndrome including, type 2 diabetes. Given the findings presented in this investigation 
regarding phenotypic changes associated with age among women with PCOS, the condition and 
associated health risks may escape detection in perimenopausal women. Evaluation the 
knowledge, attitudes, and practices of gynecologist/obstetricians, reproductive endocrinology 
and infertility, family and internal medicine specialists would provide information on the 
current practices and awareness of providers about the management of PCOS and the 
availability and access to program that could modify risk for complications inside and outside 
the reproductive window. Information garnered from such an investigation could then be used 
 
 
50 
to develop a more comprehensive and integrated approach to administer care to women with 
PCOS that would be holistically focused and include planning for healthy reproductive 
transitions (adolescence to pregnancy to menopause) and incorporate strategies for diabetes 
and CVD prevention.  
In all, these areas of investigation are rich in opportunity for advancement along a 
professional course. The later represents a linkage of public health, medicine, research, and 
health care policy and administration to advance women’s health. I look forward to the next 
phase of my career and to contributing to improved health outcomes for women and families in 
as a public health professional.  
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Table 4a. Subject characteristics at CHARM III visit 1, presented as mean (SD) or percentage (n) 
 All Age <45 years Age 45-49 Ages 50-54 Age ≥55 
Variable Cases (n=152) 
Controls 
(n=169) 
Cases 
(n=63) 
Controls 
(n=42) 
Cases 
(n=44) 
Controls 
(n=51) 
Cases 
(n=28) 
Controls 
(n=45) 
Cases 
(n=17) 
Controls 
(n=31) 
Age 
(yrs) 
47.2*** 
(5.6) 
49.5 
(5.9) 
41.9 
(2.1) 
41.9 
(2.2) 
47.5 
(1.5) 
47.8 
(1.4) 
52.4 
(1.4) 
52.6 
(1.5) 
57.3ªªª 
(1.8) 
58.1ªªª 
(2.6) 
BMI 
(kg/m2) 
33.0 *** 
(9.2) 
28.2 
(6.1) 
33.5** 
(9.8) 
28.7 
(6.7) 
32.1* 
(7.1) 
28.6 
(6.4) 
32.8* 
(9.8) 
27.8 
(6.2) 
33.7 
(11.5) 
27.5 
(4.2) 
Waist:Hip 
Ratio 
0.84 *** 
(0.08) 
0.80 
(0.08) 
0.83* 
(0.09) 
0.80 
(0.07) 
0.85* 
(0.08) 
0.81 
(0.08) 
0.85** 
(0.09) 
0.79 
(0.09) 
0.83 
(0.09) 
0.81 
(0.08) 
Natural 
Menopause 
12.6%* 
(19) 
23.1% 
(39) - - 
4.5% 
(2) 
5.9% 
(3) 
22.2%* 
(6) 
42.2% 
(19) 
64.7%ªªª 
(11) 
54.8%ªªª 
(17) 
Surgical 
Menopause 
7.3% 
(11) 
10.1% 
(17) 
4.8% 
(3) 
4.8% 
(2) 
13.6% 
(6) 
9.8% 
(5) 
3.7% 
(1) 
15.6% 
(7) 
5.9% 
(1) 
9.7% 
(3) 
BP 
Medications1 
24.1% 
(27) 
19.4% 
(21) 
21.3% 
(10) 
6.3% 
(2) 
29.4% 
(10) 
26.5% 
(9) 
20.0% 
(4) 
13.6% 
(3) 
27.3% 
(3) 
35.0% 
(7) 
Diabetes 
Medications2  
10.3%* 
(11) 
3.9% 
(3) 
9.3% 
(4) 
6.3% 
(2) 
9.4% 
(3) - 
14.3% 
(3) 
4.8% 
(1) 
9.1% 
(1) - 
Insulin3 2.0% (2) 
1.0% 
(1) - 
3.1% 
(1) 
3.0% 
(1) - 
5.0% 
(1) - - - 
Statin Use 7.2% (11) 
4.7% 
(8) 
1.6% 
(1) 
2.4% 
(1) 
9.1% 
(4) 
3.9% 
(2) 
10.7% 
(3) 
2.2% 
(1) 
17.6% 
(3) 
12.9% 
(4) 
Education 
(>12yrs) 
78.8% 
(119) 
73.2% 
(123) 
84.1% 
(53) 
78.6% 
(33) 
76.7% 
(33) 
82.0% 
(41) 
75.0% 
(21) 
73.3% 
(33) 
70.6% 
(12) 
51.6%ª 
(16) 
Race 
(% White) 
84.1% 
(127) 
79.9% 
(135) 
79.0% 
(49) 
81.0% 
(34) 
90.9% 
(40) 
76.5% 
(39) 
82.1% 
(23) 
82.2% 
(37) 
88.2% 
(15) 
80.6% 
(25) 
 
BMI-Body Mass Index; 1 BP-Blood Pressure Medications, n=112 cases and 108 controls; 2Diabetes medications, n=107 cases and 101 controls;3 Insulin, n=101 
cases and 101 controls 
Pearson’s χ2, Fisher’s exact  or Mann-Whitney-Case Control comparisons within strata; ***(p<0.001); ** (p<0.01),  *(p<0.05),  (bordered on statistical 
significance p=0.050 to 0.099); χ2 or Kruskal Wallis-comparisons between strata within cases or controls; ªªª (p<0.001), ªª (p<0.01), ª(p<0.05), ∈(bordered 
on statistical significance) 
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Table 4b. Cardiovascular disease risk factors and coronary artery calcification at CHARM III visit 1, presented as median (IQR) or percentage (n) 
 All Age <45 years Age 45-49 Ages 50-54 Age ≥55 
Variable Cases (n=152) 
Controls 
(n=169) 
Cases 
(n=63) 
Controls 
(n=42) 
Cases 
(n=44) 
Controls 
(n=51) 
Cases 
(n=28) 
Controls 
(n=45) 
Cases 
(n=17) 
Controls 
(n=31) 
Smoker 16.4% 14.2% 12.7% 21.4% 20.5% 11.8% 17.9% 13.3% 17.6% 9.7% 
SBP 
(mm Hg) 
118.0 
(109.2, 127.0) 
113.0 
(107.0, 125.0) 
114.0 
(108.0, 122.0) 
111.0 
(104.7, 118.5) 
120.0*** 
(113.0, 126.7) 
110.0 
(106.0, 122.0) 
125.0 
(110.5, 128.7) 
114.0 
(108.5, 126.0) 
119.0ª 
(107.5, 130.0) 
123.0ªªª 
(114.0, 130.0) 
DBP 
(mm Hg) 
78.0 
(70.0, 82.0) 
76.0 
(69.0, 81.0) 
75.0 
(68.0, 80.0) 
72.5 
(67.7, 80.0) 
78.5* 
(72.0, 83.0) 
74.0 
(68.0, 81.0) 
80.0 
(70.2, 82.7) 
78.0 
(69.5, 82.0) 
78.0€ 
(69.0, 80.0) 
79.0 
(72.0, 81.0) 
Chol 
(mg/dL) 
201.0 
(179.0, 228.0) 
205.0 
(184.0, 228.7) 
200.5 
(177.7, 218.0) 
193.0 
(171.7, 220.0) 
201.5 
(180.0, 227.5) 
198.0 
(184.0, 226.0) 
218.0 
(189.0, 248.5) 
216.0 
(198.0, 249.0) 
194.0 
(169.5, 239.0) 
218.0ª 
(182.0, 236.0) 
HDL 
(mg/dL) 
50.1*** 
(41.0, 63.6) 
54.7 
(46.9, 66.2) 
51.3 
(42.4, 65.0) 
52.6 
(45.9, 58.8) 
44.0** 
(39.2, 58.6) 
54.0 
(47.5, 64.8) 
51.0 
(36.7, 72.1) 
60.0 
(50.1, 70.4) 
54.4 
(48.4, 62.6) 
52.9∈ 
(46.8, 70.9) 
LDL 
(mg/dL) 
124.7 
(103.7, 145.7) 
121.5 
(98.8, 144.0) 
119,8 
(96.6, 138.4) 
123.0 
(103.6, 148.2) 
135.2 
(11.5, 150.4) 
131.8 
(101.0, 146.6) 
122.7 
(93.5, 136.7) 
124.0 
(100.7, 147.5) 
120.7 
(99.5, 145.2) 
103.5 
(94.3, 157.1) 
Trig 
(mg/dL) 
125.5* 
(82.7, 199.5) 
101.0 
(77.4, 147.7) 
97.5 
(73.7, 197.5) 
95.0 
(77.8, 123.2) 
126.0* 
(91.2, 199.5) 
100.0 
(63.0, 137.0) 
147.0 
(88.0, 244.0) 
119.0 
(74.5, 155.5) 
128.0 
(71.0, 193.0) 
115.0 
(88.5, 176.5) 
Insulin 
(µU/mL) 
16.5*** 
(10.3, 25.5) 
11.1 
(8.5, 15.6) 
18.8* 
(10.2, 27.0) 
11.9 
(9.0, 19.8) 
16.2** 
(10.0, 25.2) 
11.0 
(8.8, 15.3) 
16.4*** 
(12.6, 25.0) 
10.2 
(7.8, 14.7) 
13.9 
(8.5, 21.5) 
11.4 
(9.7, 15.6) 
Glucose 
(mg/dL) 
92.7 
(86.0, 102.3) 
91.0 
(86.6, 98.0) 
90.0 
(86.0, 97.0) 
89.0 
(85.2, 96.2) 
92.7 
(85.2, 103.2) 
90.0 
(85.0, 96.0) 
95.8 
(88.7, 107.6) 
93.6 
(86.6, 98.4) 
99.0∈ 
(86.7, 111.2) 
93.8 
(88.9, 100.0) 
Type 2 
Diab 12.5%** 3.6% 7.9% 4.8% 13.6% 3.9% 17.9% 4.4% 17.6%* 0 
HOMA 
IR 
3.8 *** 
(2.3, 6.4) 
2.5 
(1.9, 3.6) 
4.1 
(2.2, 6.1) 
2.7 
(2.0, 4.0) 
3.7** 
(2.1, 6.8) 
2.4 
(1.9, 3.4) 
4.3*** 
(3.0, 6.0) 
2.3 
(1.7, 3.4) 
3.0ª 
(2.0, 5.9) 
2.8 
(2.2, 3.6) 
CAC 
Agatson 
Score 
3.09*** 
(0,19.22) 
0 
(0, 3.78) 
1.03 
(0, 13.56) 
0 
(0, 3.26) 
2.06* 
(0, 16.39) 
0 
(0, 4.46) 
4.8*** 
(0.26, 56.56) 
0 
(0, 3.6) 
19.91**,ªª 
(1.03, 66.08) 
1.03 
(0, 3.78) 
Any CAC 63.1%*** 41.7% 55.0% 38.1% 59.1% 42.0% 75.0%** 37.8% 82.4%*,∈ 51.6% 
CAC ≥ 10 35.6%*** 14.9% 30.7% 20.9% 31.8%** 10.0% 42.9%** 13.3% 58.8%**,∈ 16.2% 
 
IQR-Interquartile Range; SBP-Systolic Blood Pressure; DBP-Diastolic Blood Pressure; HDL-High Density Lipoprotein; LDL-Low Density Lipoprotein; HOMA-Homeostatic 
Model Assessment; HOMA-IR-Insulin Resistance; CAC-Coronary Artery Calcification  
Pearson’s χ2, Fisher’s exact or Mann-Whitney-Case Control comparisons within strata; ***(p<0.001); ** (p<0.01),  *(p<0.05),  (bordered on statistical significance p=0.050 
to 0.099); χ2 or Kruskal Wallis-comparisons between strata within cases or controls; ªªª (p<0.001), ªª (p<0.01), ª(p<0.05), ∈(bordered on statistical significance) 
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Table 4c. Reproductive hormones obtained at CHARM III visit 1, presented as median (IQR) or percentage (n) 
 All Age <45 years Age 45-49 Ages 50-54 Age ≥55 
Variable Cases (n=152) 
Controls 
(n=169) 
Cases 
(n=61) 
Controls 
(n=42) 
Cases 
(n=44) 
Controls 
(n=51) 
Cases 
(n=28) 
Controls 
(n=44) 
Cases 
(n=17) 
Controls 
(n=29) 
Current 
OCs 
7.9% 
(12) 
5.9% 
(10) 
11.1% 
(7) 
11.9% 
(5) 
6.8% 
(3) 
9.8% 
(5) 
7.4% 
(2) - - - 
Current 
HRT 
11.8% 
(18) 
18.9% 
(32) 
1.6% 
(1) 
4.9% 
(2) 
18.2% 
(8) 
9.8% 
(5) 
17.9% 
(5) 
28.9% 
(13) 
23.5% 
(4) 
38.7% 
(12) 
LH 
IU/L 
9.5*** 
(4.8, 18.5) 
17.2 
(5.0, 36.4) 
6.5 
(3.8, 10.5) 
4.8 
(2.6, 7.7) 
8.4 
(3.8, 20.8) 
8.0 
(4.3, 23.3) 
13.9*** 
(8.1, 22.9) 
32.3 
(16.3, 50.4) 
25.3***, 
ªªª 
(12.3, 30.5) 
38.8 ªªª 
(28.8, 52.3) 
FSH 
IU/L 
8.0*** 
(5.0, 22.9) 
25.9 
(6.4, 62.2) 
5.3 
(4.2, 6.8) 
5.8 
(3.9, 10.8) 
9.3 
(5.2, 18.2) 
12.1 
(5.6, 32.3) 
18.5*** 
(8.3, 36.4) 
56.7 
(26.6,90.4) 
37.3***, 
ªªª 
(24.6, 44.1) 
59.3ªªª 
(43.6, 93.8) 
LH/FSH 0.81*** (0.61, 1.29) 
0.62 
(0.47, 0.85) 
1.25*** 
(0.71, 1.75) 
0.76 
(0.53, 1.12) 
0.79* 
(0.60, 1.08) 
0.63 
(0.45, 0.83) 
0.73* 
(0.55, 0.98) 
0.55 
(0.45, 0.75) 
0.64 ªªª 
(0.45, 0.73) 
0.61∈ 
(0.41, 0.75) 
E2 
pg/mL 
59.5 
(37.7, 102.3) 
57.1 
(31.7, 113.6) 
71.9 
(48.9, 128.8) 
81.1 
(44.4, 115.0) 
57.3 
(47.5, 96.8) 
62.6 
(36.4, 141.2) 
51.0 
(31.2, 83.5) 
49.7 
(28.0, 102.9) 
33.7 ª 
(26.0, 61.0) 
31.0ª 
(20.0, 93.3) 
TT 
ng/dL 
23.0** 
(19.9, 40.3) 
20.2 
(19.9, 28.8) 
25.9* 
(19.9, 43.2) 
20.1 
(19.9, 26.6) 
20.2 
(19.9, 39.6) 
23.0 
(19.9, 28.8) 
21.6 
(19.9, 43.9) 
23.0 
(19.9, 27.4) 
31.7 
(19.9, 40.3) 
19.9 
(19.9, 28.8) 
SHBG 
nmol/L 
85.4*** 
(56.2, 169.9) 
152.7 
(92.3, 230.0) 
85.6* 
(54.8, 164.2) 
144.7 
(89.9, 249.7) 
84.3*** 
(62.4, 169.9) 
170.4 
(107.9, 236.4) 
79.1 
(40.1, 204.8) 
147.9 
(75.5, 214.2) 
86.9 
(56.9, 151.6) 
119.4 
(80.0, 231.8) 
FAI 1.11*** (0.51, 2.08) 
0.57 
(0.38, 0.91) 
1.10** 
(0.51, 2.29) 
0.55 
(0.40, 0.83) 
0.93*** 
(0.51, 1.79) 
0.55 
(0.33, 0.84) 
1.07* 
(0.44, 2.78) 
0.59 
(0.41, 0.97) 
1.30** 
(0.66, 1.81) 
0.67 
(0.33, 1.23) 
FEI 0.28*** (0.12, 0.46) 
0.15 
(0.08, 0.26) 
0.34* 
(0.17, 0.52) 
0.19 
(0.11, 0.34) 
0.24* 
(0.13, 0.40) 
0.16 
(0.07, 0.26) 
0.27 
(0.09, 0.57) 
0.12 
(0.08, 0.25) 
0.14∈ 
(0.07, 0.34) 
0.11ª 
(0.05, 0.16) 
FAI/FEI 5.0* (2.8, 8.0) 
3.9 
(2.1, 7.6) 
4.4 
(2.6, 5.9) 
2.8 
(2.1, 6.4) 
4.5 
(2.69, 7.74) 
3.48 
(1.94, 5.69) 
6.5 
(3.2, 9.7) 
4.7 
(2.2, 8.4) 
7.5ªª 
(5.4, 11.2) 
7.3∈ 
(2.6, 12.6) 
 
IQR-Interquartile Range; MPA-Medroxyprogesterone Acetate; OCs-Oral Contraceptives; HRT-Hormone Replacement Therapy; LH-Luteinizing Hormone; FSH- 
Follicle Stimulating Hormone; E2-estradiol; TT-Total Testosterone; SHBG-Sex Hormone Binding Globulin; FAI-Free Androgen Index; FEI-Free Estradiol Index 
Pearson’s χ2, Fisher’s exact or Mann-Whitney-Case Control comparisons within strata; ***(p<0.001); ** (p<0.01),  *(p<0.05),  (bordered on statistical 
significance p=0.050 to 0.099); Kruskal Wallis-comparisons between strata within cases or controls; ªªª (p<0.001), ªª (p<0.01), ª(p<0.05), ∈(bordered on 
statistical significance) 
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Table 5. Reproductive profile of participants at CHARM III visit 1, presented as mean (SD) or n (%) 
Variable Cases (n=152) 
Controls 
(n=169) p 
Age (years) 47.2 (5.6) 49.5(5.9) <0.001 
Age at Menarche (years) 12.8 (1.9) 12.8 (1.7) 0.701 
Ever Pregnant 113 (74.8%) 136 (80.5%) 0.266 
Number of Pregnancies 2.6 (1.6) 2.7 (1.4) 0.156 
Number of Live Births 1.6 (1.2) 2.2(1.2) <0.001 
Fertility Medications 98 (64.9%) 14 (8.3%) <0.001 
Ever Used OCs 120 (81.1%) 132 (78.6%) 0.580 
Current OC Use 10 (6.7%) 10 (5.9%) 0.783 
Ever Used HRT 32 (21.6%) 54 (32.1%) 0.036 
Current HRT Use 18 (11.9%) 31 (18.5%) 0.101 
Natural Menopause 19 (12.6%) 39 (23.1%) <0.017 
Surgical Menopause 11 (7.3%) 17 (10.1%) 0.381 
BSO and/or Hysterectomy 22 (14.5%) 34 (20.4%) 0.680 
OCs-Oral Contraceptive; HRT-Hormone Replacement Therapy; BSO-Bilateral salpingo-oophorectomy  
P-value by χ2  or Mann-Whitney U-test 
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Table 6a. CHARM III, visit 1 characteristics of cases and controls by menopausal group presented as mean (SD), median (IQR), or percentage (n) 
Group Not Menopausal Menopausal Surgical Menopause Unknown 
Variable Cases  55%(106) 
Controls 
45%(86) 
Cases  
31%(24) 
Controls 
69%(54) 
Cases  
41%(14) 
Controls 
59%(20) 
Cases  
47%(8) 
Controls  
53%(9) 
Age 
(yrs) 
45.0 
(4.4) 
45.7 
(4.2) 
55.2 
(3.4) 
54.8 
(4.0) 
47.7 
(4.1) 
51.2 
(5.7) 
50.4 ªªª 
(3.2) 
50.4ªªª 
(2.7) 
BMI 
(kg/m2) 
33.2*** 
(9.4) 
28.3 
(6.3) 
33.1** 
(9.2) 
27.4 
(5.7) 
31.5 
(8.3) 
29.9 
(6.6) 
32.4ª 
(9.9) 
28.0 
(4.2) 
Waist:Hip 
Ratio 
0.84*** 
(0.08) 
0.80 
(0.07) 
0.88*** 
(0.08) 
0.80 
(0.08) 
0.83 
(0.09) 
0.82 
(0.08) 
0.79 
(0.09) 
0.81 
(0.09) 
Currently 
Smoking 
17.0% 
(18) 
12.8% 
(11) 
20.8% 
(5) 
13.0% 
(7) 
7.1% 
(1) 
25.0% 
(5) 
12.5% 
(1) 
11.1% 
(1) 
SBP 
(mm Hg) 
117.0** 
(109.0, 125.0) 
111.0 
(106.0, 120.0) 
121.5 
(107.7, 131.0) 
119.0 
(109.0, 128.0) 
122.5 
(109.0, 130.2) 
117.5 
(111.2, 128.5) 
121.5 
(113.0, 127.7) 
109.0ª 
(108.0, 143.0) 
DBP 
(mm Hg) 
78.0 
(70.0, 82.0) 
73.5 
(68.7, 80.0) 
78.0 
(68.5, 80.0) 
76.5 
(69.0, 82.1) 
79.5 
(70.7, 85.2) 
79.0 
(69.7, 82.7) 
77.5 
(72.0, 82.2) 
77.0 
(66.5, 81.5) 
Cholesterol 
(mg/dL) 
202.0 
(179.0, 227.0) 
199.5 
(182.0, 224.0) 
195.5 
(173.7, 241.5) 
216.0 
(191.0, 243.5) 
217.0 
(186.5, 252.5) 
213.5 
(175.5, 225.0) 
192.5 
(170.7, 197.0) 
200.0 
(168.0, 247.0) 
HDL  
(mg/dL) 
47.0** 
(39.9, 62.8) 
53.9 
(46.8, 65.0) 
53.6 
(45.4, 57.8) 
55.9 
(47.5, 69.7) 
50.7 
(45.0, 69.6) 
54.4 
(46.9, 62.5) 
52.0ª 
(42.5, 72.4) 
63.7 
(47.5, 72.8) 
LDL 
(mg/dL) 
123.6 
(102.7, 144.0) 
122.8 
(106.3, 146.5) 
103.9 
(92.5, 144.4) 
135.2 
(109.5, 148.1) 
126.7 
(95.5, 160.1) 
117.0 
(97.7, 136.9) 
106.1 
(94.1, 111.7) 
121.7 
(86.7, 156.8) 
Triglyceride 
(mg/dL) 
115.0** 
(77.5, 198.0) 
95.0 
(71.7, 129.2) 
139.0 
(87.5, 242.5) 
127.0 
(81.0, 163.5) 
121.0 
(92.5, 197.0) 
125.5 
(102.2, 191.5) 
103.5 
(79.0, 174.0) 
113.0ªª 
(75.0, 137.5) 
Insulin 
(µU/mL) 
17.8*** 
(10.0, 25.6) 
11.2 
(8.7, 16.0) 
18.0*** 
(12.3, 27.8) 
10.4 
(8.5, 14.3) 
14.0 
(9.9, 27.0) 
11.7 
(8.1, 19.2) 
13.3ª 
(10.1, 16.6) 
11.4 
(8.1, 19.3) 
Glucose 
(mg/dL) 
91.0 
(86.0, 100.6) 
90.0 
(85.0, 97.2) 
104.5** 
(89.5, 122.9) 
93.6 
(87.6, 99.0) 
92.7 
(85.0, 96.9) 
92.8 
(85.5, 98.7) 
93.3ªªª 
(88.7, 97.1) 
88.0 
(87.1, 94.0) 
Type 2 Diabetes 8.5% (9) 4.7% (4) 25.0%** (6) 1.9% (1) 28.6% (4) 5.0% (1) - - 
HOMA-IR 4.2*** (2.0, 6.3) 
2.6 
(1.9, 4.0) 
4.8*** 
(2.9, 9.9) 
2.4 
(1.9, 3.4) 
2.9 
(2.2, 6.7) 
2.5 
(1.8, 4.5) 
3.1ªª 
(2.2, 3.9) 
2.5 
(1.7, 4.9) 
CAC Agatson 
Score 
1.7*** 
(0, 14.4) 
0 
(0, 3.6) 
20.1*** 
(1.0, 61.4) 
0  
(0, 7.7) 
4.8* 
(0, 35.1) 
0.5 
(0, 3.4) 
0.7ªª 
(0, 9.2) 
1.4 
(0, 4.8) 
Any CAC 59.2%** (61) 
37.6% 
(32) 
79.2%** 
(19) 
42.6% 
(23) 
74.1% 
(10) 
50.0% 
(10) 
50.0% 
(4) 
55.6% 
(5) 
CAC ≥ 10 30.1%** (31) 
12.9% 
(11) 
58.3%** 
(14) 
22.2% 
(12) 
42.9%* 
(6) 
5.0% 
(1) 
25.0% 
(2) 
11.1% 
(1) 
IQR-Inter Quartile Range; SBP-Systolic Blood Pressure; DBP-Diastolic Blood Pressure; HDL-High Density Lipoprotein; LDL-Low Density Lipoprotein; HOMA-Homeostatic Model 
Assessment; HOMA-IR-Insulin Resistance; CAC-Coronary Artery Calcification ; Pearson’s χ2, Fisher’s exact  or Mann-Whitney-Case Control comparisons within strata; ***(p<0.001); 
** (p<0.01),  *(p<0.05),  (bordered on statistical significance p=0.050 to 0.099);  Kruskal Wallis-comparisons between strata within cases or controls; ªªª (p<0.001), ªª (p<0.01), 
ª(p<0.05), ∈(bordered on statistical significance) 
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Table 6b. CHARM III, visit 1 reproductive characteristics of cases and controls by menopausal group presented as median (IQR) or percentage (n) 
Group Not Menopausal Menopausal Surgical Menopause Unknown 
Variable Cases  55%(106) 
Controls 
45%(86) 
Cases  
31%(24) 
Controls 
69%(54) 
Cases  
41%(14) 
Controls 
59%(20) 
Cases  
47%(8) 
Controls  
53%(9) 
Current OC 9.5%  (10) 
8.1% 
(7) - - - - 
33.3% 
(3) 
25.0% 
(2) 
Duration OCs 
(months) 
24.0 
(6.0, 72.0) 
48.0 
(5.2, 108.0) 
6.0 
(0, 33.0) 
12.0 
(0, 111.0) 
12.0 
(0.7, 25.5) 
8.0 
(0, 51.0) 
36.0 
(0.7, 156.0) 
72.0 
(54.0, 172.5) 
Current HRT - - 20.8% (5) 
27.8% 
(15) 
57.1% 
(8) 
57.9% 
(11) 
62.5% 
(5) 
66.7% 
(6) 
Duration HRT 
(months) - - 
0 
(0, 21.0) 
4.0 
(0, 60.0) 
36.0 
(0, 111.0) 
6.0 
(0, 60.0) 
0 
(0, 5.2) 
8.0 
(0, 66.0) 
Duration 
Menopause 
(mo) 
- - 
39.5 
(31.0, 82.1) 
n=15 
59.3 
(18.8, 96.9) 
n=36 
62.7 
(43.6, 275.5) 
n=8 
96.5 
(51.4, 133.3) 
n=18 
- - 
LH 
IU/L 
7.0 
(3.8, 12.2) 
5.6 
(3.5, 14.5) 
25.4*** 
(14.0, 29.5) 
38.7 
(28.8, 55.3) 
17.7 
(10.9, 27.4) 
32.2 
(17.5, 48.7) 
5.7ªªª 
(3.8, 11.4) 
9.4ªªª 
(3.9, 12.0) 
FSH 
IU/L 
5.9 
(4.5, 9.6) 
7.0 
(4.4, 24.4) 
38.0*** 
(24.9, 45.1) 
74.7 
(48.2, 96.8) 
25.1* 
(13.4, 40.8) 
48.1 
(35.1, 64.0) 
7.7ªªª 
(5.6, 10.5) 
13.4ªªª 
(4.5, 25.6) 
LH:FSH 0.95*** (0.67, 1.59) 
0.74 
(0.51, 1.03) 
0.63 
(0.48, 0.78) 
0.55 
(0.44, 0.70) 
0.74 
(0.53, 0.98) 
0.61 
(0.50, 0.74) 
0.72ªªª 
(0.47, 0.99) 
0.58ªªª 
(0.32, 0.91) 
E2 
pg/mL 
71.5 
(49.6, 119.2) 
76.8 
(45.1, 142.3) 
36.6 
(25.5, 61.9) 
32.9 
(21.1, 60.7) 
49.1 
(26.8, 57.2) 
53.7 
(29.4, 119.9) 
46.5ªªª 
(22.6, 77.2) 
85.3ªªª 
(42.7, 156.7) 
TT 
ng/dL 
24.5 
(19.9, 42.5) 
23.0 
(19.9, 28.8) 
31.7 
(19.9, 42.5) 
20.2 
(19.9, 28.8) 
21.6 
(19.9, 41.8) 
21.6 
(19.9, 28.1) 
19.9 
(19.9, 31.7) 
19.9 
(19.9, 20.0) 
SHBG 
nmol/L 
79.0*** 
(56.3, 160.0) 
158.2 
(100.1, 224.8) 
85.9* 
(55.6, 163.5) 
132.7 
(79.0, 210.8) 
100.0 
(55.1, 206.7) 
155.7 
(61.6, 299.0) 
132.7, ªªª 
(63.8, 217.8) 
214.8ªªª 
(117.2, 300.2) 
FAI 1.06*** (0.51, 2.19) 
0.61 
(0.42, 0.84) 
1.32** 
(0.69, 1.97) 
0.63 
 (0.41, 0.98) 
1.22 
(0.34, 2.56) 
0.50 
(0.24, 1.46) 
0.72, ªªª 
(0.33, 1.22) 
0.32ªªª 
(0.23, 0.59) 
FEI 0.32** (0.14, 0.52) 
0.19 
(0.11, 0.33) 
0.18** 
(0.07, 0.31) 
0.10 
(0.05, 0.16) 
0.18 
(0.09, 0.36) 
0.17 
(0.09, 0.26) 
0.28ªªª 
(0.04, 0.40) 
0.17ªªª 
(0.06, 0.47) 
FAI/FEI 4.2* (2.4, 6.4) 
2.9 
(2.0, 5.5) 
8.6 
(5.5, 11.0) 
7.4 
(3.8, 11.7) 
6.4 
(4.4, 13.6) 
4.7 
(1.9, 6.6) 
5.1,ªªª 
(2.5, 9.7) 
2.2ªªª 
(1.2, 4.5) 
IQR-Inter Quartile Range; HRT/OCs-current Hormone Replacement Therapy or Oral Contraceptives;  LH-Luteinizing Hormone; FSH- Follicle Stimulating Hormone; E2-Estradiol; TT-
Total Testosterone; SHBG-Sex Hormone Binding Globulin; FAI-Free Androgen Index; FEI-Free Estradiol Index 
Pearson’s χ2, Fisher’s exact  or Mann-Whitney-Case Control comparisons within strata; ***(p<0.001); ** (p<0.01),  *(p<0.05),  (bordered on statistical significance p=0.050 to 0.099);  
Kruskal Wallis-comparisons between strata within cases or controls; ªªª (p<0.001), ªª (p<0.01), ª(p<0.05), ∈(bordered on statistical significance) 
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Table 7. Estimated parameters, adjusted R2 from multiple linear regression equations for predictors of 
cardiovascular disease risk factors that differed between cases and controls 
Models Independent variable SBP HDL Trig* 
1 
PCOS 
β (95% CI) 
(p value) 
Adjusted R2 
1.642 
(-1.229, 4.513) 
p=0.261 
0.001 
-5.061 
(-8.372, -1.751) 
p=0.003 
0.026 
0.178 
(0.048, 0.309) 
p=0.007 
0.020 
2 
PCOS 
 
 
Age 
 
 
BMI 
 
 
Adjusted R2 
0.538 
(-2.270, 3.346) 
p=0.706 
0.563 
(0.338, 0.788) 
p<0.001 
0.519 
(0.349, 0.689) 
p<0.001 
0.157 
-1.771 
(-5.109, 1.567) 
p=0.297 
0.248 
(-0.021, 0.517) 
p=0.071 
-0.573 
(-0.775, -0.371) 
p<0.001 
0.123 
0.128 
(-0.007, 0.260) 
p=0.058 
0.017 
(0.006, 0.027) 
p=0.002 
0.019 
(0.011, 0.027) 
p<0.001 
0.104 
3 
PCOS 
 
 
Age 
 
 
BMI 
 
 
Not 
Menopausal 
 
Natural 
Menopause 
 
Surgical  
Menopause 
 
Adjusted R2 
0.490 
(-2.334, 3.313) 
p=0.733 
0.629 
(0.346, 0.687) 
p<0.001 
0.517 
(0.346, 0.687) 
p<0.001 
0 
 
-1.561 
(-5.826, 2.705) 
p=0.472 
1.630 
(-2.864, 6.123) 
p=0.476 
0.156 
-1.729 
(-5.093, 1.634) 
p=0.312 
0.229 
(-0.136, 0.594) 
p=0.218 
-0.574 
(-0.777, -0.371) 
p<0.001 
0 
 
0.279 
(-4.808, 5.366) 
p=0.914 
1.280 
(-4.070, 6.629) 
p=0.638 
0.118 
0.139 
(0.008, 0.271) 
p=0.038 
0.010 
(-0.004, 0.024) 
p=0.166 
0.019 
(0.011, 0.027) 
p<0.001 
0 
 
0.113 
(-0.086, 0.313) 
p=0.265 
0.275 
(0.065, 0.485) 
p=0.010 
0.118 
*Trig-Triglyceride levels were log transformed prior to entry into model.  
BMI-Body Mass Index; SBP-Systolic Blood Pressure; HDL-High Density Lipoprotein cholesterol 
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Table 7 continued 
 
Model Independent Variable SBP HDL Trig* 
4 
PCOS 
 
 
Age 
 
 
BMI 
 
 
Not 
Menopausal 
Natural 
Menopause 
 
Surgical 
Menopause 
 
PCOS* 
Menopause 
 
Adjusted R2 
0.760 
(-2.685, 4.205) 
p=0.665 
0.628 
(0.322, 0.934) 
p<0.001 
0.516 
(0.346, 0.687) 
p<0.001 
0 
 
-1.250 
(-6.087, 3.588) 
p=0.612 
1.991 
(-3.226, 7.209) 
p=0.453 
-0.781 
(-6.479, 4.916) 
p=0.787 
0.154 
-1.852 
(-5.957, 2.253) 
p=0.375 
0.229 
(-0.136, 0.595) 
p=0.218 
-0.573 
(-0.777, -0.370) 
p<0.001 
0 
 
0.136 
(-5.642, 5.914) 
p=0.963 
1.115 
(-5.099, 7.329) 
p=0.724 
0.356 
(-6.440, 7.153) 
p=0.918 
0.115 
0.155 
(-0.006, 0.316) 
p=0.058 
0.010 
(-0.004, 0.024) 
p=0.168 
0.019 
(0.011, 0.027) 
p<0.001 
0 
 
0.132 
(-0.095, 0.358) 
p=0.253 
0.296 
(0.053, 0.540) 
p=0.017 
-0.046 
(-0.313, 0.220) 
p=0.732 
0.116 
5 
PCOS 
 
 
Age 
 
 
BMI 
 
Not 
Menopausal 
Natural 
Menopause 
 
Surgical 
Menopause 
 
PCOS* 
Menopause 
 
Taking 
Hormones 
 
Adjusted R2 
0.679 
(-2.764, 4.121) 
p=0.698 
0.650 
(0.343, 0.956) 
p<0.001 
0.531 
(0.360, 0.703) 
p<0.001 
0 
-1.857 
(-6.756, 3.042) 
p=0.456 
0.380 
(-5.270, 6.029) 
p=0.895 
-0.367 
(-6.074, 5.341) 
p=0.899 
1.662 
(-2.076, 5.401) 
p=0.382 
0.156 
-2.086 
(-6.164, 1.992) 
p=0.315 
0.236 
(-0.128, 0.600) 
p=0.204 
-0.541 
(-0.744, -0.337) 
p<0.001 
0 
-0.935 
(-6.747, 4.876) 
p=0.752 
-1.847 
(-8.536, 4.843) 
p=0.587 
0.660 
(-6.106, 7.426) 
p=0.848 
5.819 
(1.363, 10.275) 
p=0.011 
0.131 
0.147 
(-0.012, 0.306) 
p=0.069 
0.012 
(-0.002, 0.026) 
p=0.097 
0.020 
(0.012, 0.028) 
p<0.001 
0 
0.074 
(-0.155, 0.302) 
p=0.519 
0.140 
(-0.153, 0.439) 
p=0.290 
-0.011 
(-0.311, 0.296) 
p=0.937 
0.182 
(0.008, 0.356) 
p=0.040 
0.129 
*Trig-Triglyceride levels were log transformed prior to entry into model.  
BMI-Body Mass Index; SBP-Systolic Blood Pressure; HDL-High Density Lipoprotein cholesterol 
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Table 8. Logistic regression models of CAC (<10 vs. ≥10) between PCOS cases and controls (n=300) 
Models β SE OR 95% CI for OR p Value 
1. PCOS 1.159 0.282 3.187 1.832, 5.545 <0.001 
2. PCOS 
Age 
Body Mass Index 
0.778 
0.060 
0.173 
0.338 
0.028 
0.025 
2.176 
1.061 
1.189 
1.121, 4.223 
1.055, 1.120 
1.132, 1.248 
0.022 
0.031 
<0.001 
3. PCOS            
Not Menopausal (n=188) 
Natural Menopause (n=78) 
Surgical Menopause (n=34) 
1.384 
 
0.961 
0.079 
0.304 
 
0.329 
0.478 
3.991 
1 
2.614 
1.082 
2.200, 7.240 
 
1.371, 4.985 
0.424, 2.763 
<0.001 
 
0.004 
0.869 
4. PCOS 
Age 
            BMI 
Not Menopausal 
Natural Menopause 
Surgical Menopause  
0.869 
-0.009 
0.183 
 
1.519 
0.089 
0.353 
0.038 
0.026 
 
0.536 
0.566 
2.385 
0.991 
1.201 
1 
4.570 
1.093 
1.195, 4.762 
0.920, 1.068 
1.141, 1.264 
 
1.599, 13.060 
0.361, 3.315 
0.014 
0.814 
<0.001 
 
0.005 
0.875 
5. PCOS 
Age 
BMI 
Not Menopausal 
Natural Menopause 
Surgical Menopause  
PCOS*Menopause 
0.433 
-0.005 
0.184 
 
0.985 
-0.541 
1.001 
0.456 
0.038 
0.026 
 
0.645 
0.726 
0.702 
1.541 
0.995 
1.202 
1 
2.679 
0.582 
2.722 
0.631, 3.766 
0.923, 1.073 
1.142, 1.266 
 
0.757, 9.483 
0.140, 2.418 
0.688, 10.771 
0.342 
0.899 
<0.001 
 
0.126 
0.457 
0.154 
BMI-Body Mass Index; CAC-Coronary Artery Calcification 
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Table 9. Descriptive characteristics of participants at CHARM III visit 1 matched for age 
and race, presented as mean (SD) or percentage (n) 
Variable Cases (n=83) 
Controls 
(n=83) 
Age (years) 47.6 (5.8) 
47.6 
(5.6) 
BMI (kg/m2) 33.5*** (9.5) 
27.5 
(5.6) 
Waist:Hip Ratio 0.85*** (0.08) 
0.79 
(0.07) 
Age at Menarche (years) 13.1 (2.2) 
12.7 
(1.6) 
Not Menopausal 73.5% (61) 
81.9% 
(68) 
Natural Menopause 18.1% (15) 
27.7% 
(23) 
Pearson 2 or Mann-Whitney ***(p<0.001); ** (p<0.01),  *(p<0.05),  (bordered on statistical 
significance p=0.050 to 0.099) 
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Table 10. Subject characteristics at CHARM III visit 1, presented as mean (SD) or percentage (n) 
 Not Menopausal Menopausal 
Variable Cases 53%(68) 
Controls 
47%(60) 
Cases 
44%(18) 
Controls  
56%(23) 
Age 
(yrs) 
45.9 
(4.5) 
45.2 
(4.2) 
55.6 
(3.5) 
54.1 
(3.6) 
BMI 
(kg/m2) 
33.1*** 
(9.4) 
27.3 
(4.8) 
35.4* 
(10.3) 
28.1 
(7.2) 
Waist:Hip 
Ratio 
0.84*** 
(0.08) 
0.79 
(0.07) 
0.89** 
(0.08) 
0.80 
(0.09) 
Age at 
Menarche 
(yrs) 
13.3 
(2.2) 
12.5 
(1.3) 
12.3 
(2.1) 
13.0 
(2.3) 
Duration of 
Menopause 
(months) 
- - 61.5 (58.5) 
60.5 
(50.4) 
LH 10.9 (8.7) 
11.3 
(14.9) 
23.1*** 
(11.0) 
50.2 
(22.0) 
FSH 11.5 (13.0) 
17.3 
(31.0) 
35.5*** 
(15.5) 
94.5 
(41.0) 
LH:FSH 
Ratio 
1.21** 
(0.77) 
0.95 
(0.91) 
0.67* 
(0.17) 
0.54 
(0.12) 
Estradiol 97.4 (62.9) 
113.7 
(109.4) 
40.4 
(20.1) 
31.0 
(14.4) 
Total 
Testosterone 
36.1 
(32.5) 
26.1 
(10.0) 
37.7 
(20.2) 
29.4 
(14.5) 
SHBG 129.6*** (125.5) 
162.9 
(83.9) 
94.6* 
(74.6) 
139.5 
(77.9) 
FAI 1.66*** (1.60) 
0.70 
(0.44) 
2.62** 
(3.78) 
0.92 
(0.61) 
FEI 0.47** (0.48) 
0.29 
(0.25) 
0.28** 
(0.32) 
0.10 
(0.06) 
FAI/FEI 4.44 (3.21) 
3.39 
(2.40) 
9.38 
(3.34) 
9.91 
(4.80) 
Mann-Whitney-Case Control comparisons within strata; ***(p<0.001); ** (p<0.01),  *(p<0.05),  (bordered on 
statistical significance p=0.050 to 0.099) 
64 
 
 
Table 11. Cardiovascular disease risk factors and coronary artery calcification at CHARM III visit 1, 
presented as mean (SD) or percentage (n) 
 Not Menopausal Menopausal 
Variable Cases 53%(68) 
Controls 
47%(60) 
Cases 
44%(18) 
Controls  
56%(23) 
Smoker 23.5% (16) 
15.0% 
(9) 
20.0% 
(3) 
13.0% 
(3) 
SBP 
(mm Hg) 
117.9*** 
(11.0) 
112.5 
(14.3) 
120.2 
(13.8) 
118.5 
(12.9) 
DBP 
(mm Hg) 
76.0* 
(8.4) 
72.7 
(8.4) 
75.1 
(10.2) 
74.7 
(8.4) 
Chol 
(mg/dL) 
208.9 
(42.8) 
203.2 
(35.0) 
212.3 
(44.1) 
211.9 
(34.1) 
HDL 
(mg/dL) 
50.3** 
(16.9) 
55.3 
(12.0) 
53.8 
(13.6) 
55.1 
(14.8) 
LDL 
(mg/dL) 
130.28 
(35.3) 
126.7 
(30.0) 
120.2 
(34.8) 
129.7 
(32.3) 
Trig 
(mg/dL) 
148.0 
(108.1) 
105.8 
(48.5) 
205.2 
(193.6) 
129.6 
(76.6) 
Insulin 
(U/mL) 
18.7*** 
(10.8) 
11.7 
(4.6) 
23.0** 
(10.9) 
15.0 
(10.9) 
Glucose 
(mg/dL) 
94.9 
(14.0) 
96.3 
(37.5) 
119.3* 
(40.9) 
93.0 
(10.5) 
Type 2 Diab 10.3% (7) 
1.7% 
(1) 
33.3%** 
(5) 0 
HOMA 
IR 
4.6*** 
(3.3) 
2.9 
(2.8) 
7.2*** 
(4.6) 
3.6 
(3.0) 
CAC Agatson 
Score 
13.4*** 
(31.7) 
5.4 
(26.6) 
119.7* 
(249.7) 
18.1 
(46.1) 
Any CAC 60.6%*** (40) 
30.0% 
(18) 
80.0%* 
(12) 
39.1% 
(9) 
CAC ≥ 10 25.7%* (17) 
10.0% 
(6) 
60.0%* 
(9) 
26.1% 
(6) 
Pearson 2, Fisher’s exact, or Mann-Whitney-Case Control comparisons within strata; ***(p<0.001); ** (p<0.01),  
*(p<0.05),  (bordered on statistical significance p=0.050 to 0.099 
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Table 12. CHARM III, Visit 1 number of cycles/years reported by cases and control when not 
using hormones or pregnant, presented a median (IQR) 
 Teens 20s 30s 40s Total 
Cases 
 
8.0 (4.0, 12.0) 
n=134 
5.0 (2.4, 9.2) 
n=134 
8.8 (4.3,11.8) 
n=133 
12.0 (9.1, 12.0) 
n=119 
7.9 (5.3, 9.7) 
n=132 
Controls 
 
12.0 (10.3, 12.0) 
n=147 
8.6 (2.8, 11.0) 
n=148 
11.0 (9.4, 12.0) 
n=148 
12.0 (11.0, 12.0) 
n=136 
10.0 (7.9, 11.1) 
n=145 
p value* <0.001 0.002 <0.001 0.006 <0.001 
*Mann-Whitney 
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Table 13. Characteristics of women with PCOS at CHARM III visit 1, stratified by adjusted 
cumulative cycle number per reproductive years contributed, shown as mean (SD) or percent (n) 
Variable < 9 cycles n=53 
9-11 cycles/year 
n=37 
>11 cycles/year 
n=48 p* 
Adjusted Cycle #/ yr 6.5 (1.8) 10.0 (0.52) 12.0 (0.86) <0.001
Natural Cycle #/yr 5.2 (1.9) 7.9 (2.2) 9.5 (2.5) <0.001
Age at visit (yrs) 46.6 (6.1) 47.6 (5.9) 46.5 (4.4) 0.685 
BMI (kg/m2) 33.6 (8.4) 33.3 (9.3) 32.4 (10.1) 0.614 
Waist:Hip ratio 0.85 (0.09) 0.84 (0.07) 0.83 (0.09) 0.674 
Education (>12 yrs.) 75.0% (39) 91.9% (34) 79.2% (38) 0.124 
Race  (% White) 81.1% (43) 77.8% (28) 89.6% (43) 0.313 
Menarche (yrs) 13.2 (2.2) 12.4 (1.5) 12.7 (1.9) 0.316 
Period last 12 mos. 77.4% (41) 73.0% (27) 75.0% (36) 0.891 
Natural Menopause 17.0% (9) 8.3% (3) 4.2% (2) 0.095 
Surgical Menopause 5.7% (3) 2.8% (1) 10.4% (5) 0.343 
Ever Pregnant 75.5% (40) 81.1% (30) 72.9% (35) 0.676 
Fertility Treatments 71.7% (38) 56.8% (21) 62.5% (30) 0.363 
# Pregnancies 2.4 (1.2) 2.6 (2.0) 2.9 (1.7) 0.535 
# Live Births 1.7 (0.9) 1.7 (1.3) 1.5 (1.4) 0.479 
Current OCs 7.5% (4) 8.1% (3) 10.4% (5) 0.868 
Current HRT 5.7% (3) 13.5% (5) 14.6% (7) 0.296 
LH (IU/L) 12.0 (8.8) 12.9 (9.7) 12.9 (14.4) 0.424 
FSH (IU/L) 13.3 (12.8) 17.1 (15.0) 15.6 (20.4) 0.244 
LH/FSH 1.1 (0.67) 1.0. (0.6) 1.0 (0.7) 0.395 
E2 (pg/mL) 81.3 (76.7) 77.9 (60.0) 86.1 (65.8) 0.584 
TT (ng/dL) 55.3 (97.9) 30.6 (14.9) 27.7 (13.5) 0.003 
SHBG (nmol/L) 120.3 (103.7) 131.8 (124.3) 151.5 (144.5) 0.460 
FAI 2.60 (3.48) 1.45 (1.31) 1.15 (1.11) 0.015 
FEI 0.38 (0.32) 0.41 (0.51) 0.36 (0.40) 0.697 
FAI:FEI ratio 8.89 (16.5) 5.79 (3.94) 5.07 (4.58) 0.014 
Current Smoker 13.2% (7) 13.5% (5) 22.9% (11) 0.355 
Type 2 Diabetes 13.2% (7) 8.1% (3) 10.4% (5) 0.741 
Insulin (U/mL) 20.9 (12.0) 18.3 (11.1) 18.2 (12.7) 0.382 
Glucose (mg/dL) 101.8 (28.9) 95.2 (21.1) 94.8 (13.2) 0.394 
HOMA-IR 5.7 (4.9) 4.5 (3.3) 4.5 (3.7) 0.362 
SBP (mm Hg) 117.3 (10.9) 118.6 (11.5) 118.1 (10.5) 0.852 
DBP (mm Hg) 76.3 (8.5) 77.1 (8.1) 75.1 (7.4) 0.589 
Cholesterol (mg/dL) 215.7 (51.5) 205.1 (37.5) 201.2 (35.4) 0.548 
HDL (mg/dL) 51.3 (15.3) 52.6 (17.9) 53.7 (14.3) 0.621 
LDL (mg/dL) 131.8 (49.1) 119.2 (34.3) 122.0 (29.2) 0.610 
Triglyceride (mg/dL) 170.7 (133.4) 161.5 (124.7) 127.0 (75.8) 0.157 
CAC Agatson Score 40.5 (142.8) 17.9 (27.3) 15.3 (29.1) 0.319 
Any CAC 67.3% (35) 67.6% (25) 52.2% (24) 0.223 
CAC ≥ 10 34.6% (18) 45.9% (17) 28.3% (13) 0.243 
HRT- Hormone Replacement Therapy; OCs- Oral Contraceptives; BMI-Body Mass Index; LH-Luteinizing Hormone; FSH- 
Follicle Stimulating Hormone; E2-Estradiol; TT-Total Testosterone; SHBG-Sex Hormone Binding Globulin;FAI-Free 
Androgen Index; FEI-Free Estradiol Index; SBP-Systolic Blood Pressure; DBP-Diastolic Blood Pressure; HDL-High 
Density Lipoprotein; LDL-Low Density Lipoprotein; HOMA-IR-Homeostatic Model Assessment Insulin Resistance; CAC-
Coronary Artery Calcification 
*2 or Kruskal-Wallis for p values 
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Table 14. Logistic regression models of Coronary Artery Calcification (<10 vs. 10) in PCOS 
cases (n=142) using lifetime irregularity as a predictor 
Models  SE OR 95% CI for OR p Value 
1. Total Adjusted 
Cycles (TAC) 
0.001 0.002 1.001 0.998, 1.004 0.519 
2. TAC 
Age 
0.000 
0.084 
0.002 
0.034 
1.000 
1.088 
0.996, 1.003 
1.018, 1.162 
0.880 
0.013 
3. TAC 
Age 
*HOMA-IR 
0.001 
0.102 
1.263 
0.002 
0.038 
0.303 
1.001 
1.107 
3.535 
0.997, 1.005 
1.029, 1.192 
1.950, 6.406 
0.580 
0.007 
<0.001 
*HOMA-IR-Homeostatic Model Assessment Insulin Resistance; log transformed values used in model 
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Table 15. Selected outcomes in PCOS cases and controls matched for age +/- 1 year at CHARM 
III Visit 1 (baseline) and Visit 3 (follow-up), presented as mean (SD), frequency, and % change 
 Cases (n=28) Controls (n=28) p* 
Variable Visit 1 Visit 3 % change Visit 1 Visit 3 % change  
Age yrs 44.7 (2.5) 
47.38 
(2.8) 
6.8  
(2.5) 
44.8 
( 2.5) 
47.7  
(2.6) 
6.3  
(0.8) 0.43 
BMI kg/m2 30.3 (8.4) 
30.1 
(8.1) 
0.04  
(6.96) 
28.6 
(5.0) 
28.6 
 (5.2) 
-0.74 
(7.05) 0.93 
Waist/Hip 
Ratio 
0.82 
(0.07) 
0.83 
(0.09) 
1.09  
(7.19) 
0.80 
(0.07) 
0.81 
(0.06) 
0.54  
(5.89) 0.63 
HOMA-IR 4.1  (2.9) 
5.1  
(6.0) 
42.5 
(142.4) 
2.9  
(1.5) 
2.6 
(1.5) 
1.7 
(45.7) 0.28 
LH IU/L 7.4 (7.6) 
19.4 
(26.4) 
389 
(1030) 
7.9  
(8.4) 
14.7 
(16.7) 
175 
(530) 0.46 
FSH IU/L 8.1  (12.7) 
18.2 
(23.7) 
293 
(620) 
11.7 
(14.2) 
22.8 
(29.3) 
189  
(513) 0.38 
LH/FSH 
Ratio 
1.10 
(0.57) 
1.33 
(0.94) 
28.3 
(69.4) 
0.95 
(1.11) 
0.88 
(0.41) 
48  
(134) 0.92 
E2 pg/mL 83.2 (46.1) 
114.3 
(102.1) 
68.8 
(180.1) 
70.0 
(39.2) 
102.7 
(106.1) 
76  
(194) 0.95 
TT ng/dL 28.0 (13.5) 
24.7 
(13.4) 
-8.5 
(47.8) 
24.9  
(7.4) 
18.8 
(12.0) 
-23.2 
(51.4) 0.14 
SHBG 
nmol/L 
 139.1 
(115.9) 
104.3 
(66.7) 
-13.4 
(56.0) 
180.8 
(113.2) 
122.3 
(80.7) 
-27.1 
(34.4) 0.34 
FAI 1.09 (0.97) 
1.20 
(0.87) 
32.2  
(77.4) 
0.62 
(0.35) 
0.73 
(0.63) 
31.9 
(115.1) 0.30 
FEI 0.32 (0.22) 
0.55 
(0.48) 
142 
(242) 
0.18 
(0.14) 
0.39 
(0.46) 
147 
(263) 0.87 
FAI/FEI 4.39 (3.32) 
3.92 
(5.41) 
-7.8 
(82.1) 
4.52 
(2.87) 
3.09 
(2.89) 1.5 (117) 0.46 
AMH 
ng/mL 
1.22 
(1.11) 
0.50 
(0.72) 
-49.6 
(32.5) 
0.83 
(1.72) 
0.60 
(1.49) 
-17.5 
(43.2) 0.004 
% change= (V3-V1)/V1*100 
BMI-Body Mass Index; HOMA-IR-Homeostatic Model Assessment Insulin Resistance; LH-Luteinizing Hormone; FSH- 
Follicle Stimulating Hormone; E2-Estradiol; TT-Total Testosterone; SHBG-Sex Hormone Binding Globulin; FAI-Free 
Androgen Index; FEI-Free Estradiol Index 
*Mann-Whitney p value 
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9.0 FIGURES 
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Figure 2. Age distributions of cases and controls at CHARM III visit 1. Panel A (Top) includes all cases 
(n=152) and controls (n=169). Panel B (bottom) includes 83 case control pairs sequentially matched for 
age  one year and ethnicity. 
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BSO: Bilateral Salpingo-oophorectomy Surgery NS: Not Specified 
Tx: Drug Treatment                POF: Premature Ovarian Failure 
 
Figure 3. Reasons menses stopped in cases and controls evaluated at CHARM III visit 1 
 
 
Figure 4. Distribution of reproductive status across cases and controls   
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Panel A-Systolic Blood Pressure; Panel B-High Density Lipoprotein (HDL); Panel C Triglycerides*-Log 
transformed 
 
Figure 5. Evaluation of possible interactions on selected cardiovascular disease risk factors in 
control and PCOS case subjects in CHARM III, visit 1 by reproductive status 
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Figure 6. Average number of natural cycles/year at each decade in PCOS cases and controls  
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APPENDIX A: CHARM III QUESTIONNAIRE 
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